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Abstract 
Prostate cancer (PC) is the most common cancer in men. In the UK alone, 
there are over 30,000 men diagnosed with PC every year. Loss of SPRY2 and 
activation of receptor tyrosine kinases are common events in PC. However, the 
molecular  basis  of  their  interaction  and  clinical  impact  remains  to  be  fully 
examined. SPRY2 loss may functionally synergise with aberrant cellular signalling 
to drive PC and to promote treatment resistant disease. Using a combination of 
in vitro, pre-clinical in vivo models and clinical PC, this thesis shows the impact 
of  SPRY2  loss  upon  activation  of  the  ErbB  signalling  system  via  a  positive 
feedback  regulation  of  the  ErbB-PI3K/AKT  cascade.  Loss  of  SPRY2  resulted  in 
hyper-activation  of  PI3K/AKT  signalling  to  drive  proliferation  and  invasion  by 
enhanced  internalisation  of  EGFR/HER2  and  their  sustained  localisation  and 
signalling  at  the  early  endosome  in  a  PTEN-dependent  manner.  This  involves 
activation  of  p38  MAPK  by  PI3K  to  facilitate  clathrin-mediated  ErbB  receptor 
endocytosis. Furthermore, this thesis suggests a critical role of PI3K/AKT in PC 
whereby  in  vitro  and  in  vivo  inhibition  of  PI3K  suppresses  proliferation  and 
invasion,  supporting  PI3K/AKT  as  a  target  for  therapy  particularly  in  patients 
with  PTEN-haploinsufficiency,  low  SPRY2  and  ErbB  expressing  tumours.  In 
conclusion, SPRY2 is an important tumour suppressor in PC; its loss drives the 
PI3K/AKT pathway via functional interaction with the ErbB system. 
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1. Introduction 
1.1 Prostate Cancer 
1.1.1 Natural history of prostate cancer 
  In 2007, there were around 36,100 men diagnosed with prostate 
cancer (PC) in the UK alone, and around 913,000 men were diagnosed with PC 
worldwide (CRUK 2010). Although the cancer death rate has decreased steadily 
since 1990s, prostate cancer remains the second most common cause of cancer 
death  in  UK  men,  after  lung  cancer.  Such  improvement  in  survival  may  be 
attributed to the increased use of prostate-specific antigen (PSA) testing. PSA, 
as a biomarker, revolutionised the diagnosis of prostate cancer. It allows the 
detection of prostate tumours at early stage, and the test procedure is easy and 
straightforward. Despite a vast increase in the diagnosis of PC, PSA testing is not 
able to differentiate between latent and life-threatening tumours reliably at the 
time of diagnosis. Patients with raised PSA levels typically undergo biopsy to 
assess  the  potential  presence  of  cancerous  disease.  The  biopsy  samples  are 
analysed  according  to  the  histopathological  grading  system  called  Gleason 
scoring, which classifies cancer from 1 to 5 based on histological appearance and 
tissue architecture (Mellinger et al., 1967, Epstein, 2010). In addition, patients 
are diagnosed with various stages based on the status of the primary tumours, 
including  invasive  disease  (T1-4),  lymph  node  involvement  (N0-1),  and 
metastatic PC (M0 and 1a-c) (Ohori et al., 1994, Falzarano and Magi-Galluzzi, 
2011). Once early prostate cancer is diagnosed, the conventional treatment in 
UK includes external beam radiation therapy, brachytherapy, surgery and active 
surveillance with intent for deferred intervention. In addition castration for the 
treatment of advanced prostate cancer was such an important advance in the 
clinic  that  earned  Charles  Huggins  a  Nobel  Prize  in  1966  (Huggins,  1967). 
Historically  ancient  Egyptians  first  described  PC  as  a  clinical  disease,  and 
surgical castration reduces initial tumour burden by depleting androgen level, 
but eventually results castration-resistant disease. Unfortunately, to date such 
advanced PC remains incurable; current docetaxel-based chemotherapy or PC 
vaccine only extends patient survival up to 3-4 months (Petrylak, 2005, Jathal et 
al., 2011). This highlights the critical need for improved molecular markers and  
    15 
other  approaches  by  basic  scientific  research  and  preclinical  models  to 
complement  the  existing  assessments  of  PC  for  more  effective  prognosis  and 
treatment. 
1.1.2 Prostatic intraepithelial neoplasia (PIN) and metastatic prostate cancer 
Prostate  cancer  is  widely  considered  as  a  progressive  disease  often 
involving sequential deregulation of molecular processes and pathways (Figure 
1.1.1). The progression was described as from normal epithelium to PIN, then 
more aggressive adenocarcinoma and metatstasis. In 1987 Bostwick and Brawer 
first  proposed  the  term  PIN  to  describe  low  grade  PC  (Bostwick  and  Brawer, 
1987). PIN is defined as a histological interpretation of cellular enhancement of 
the  normal  glandular  architecture  with  cytological  abnormality  including 
enlargement  of  nuclei  and  nucleoli,  and  cytoplasmic  hyperchromasia.  PC  is 
generally considered as a multifocal disease with formation of heterogenous foci 
and  advanced  metastasis  to  secondary  organs.  The  heterogeneity  is  also 
observed in PIN with involvement of multiple clusters of glandular structures. In 
addition,  the  exhibition  of  increased  cell  proliferation  markers  in  prostate  is 
considered as high grade PIN (Bostwick, 1989, Shappell et al., 2004).  
 
Advanced PC often metastasises to distant organs including lung, liver and 
pleura. Interestingly, bone metastasis occurs inevitably with unknown reason in 
advanced PC patients, where it leads to osteoblastic lesions (Bubendorf et al., 
2000, Logothetis and Lin, 2005). Such complication in bones is incurable and a 
major cause of morbidity for advanced PC patients, which creates another level 
of clinical challenge. Recent studies detected circulating prostate tumour cells 
Prostatic intraepithelial neoplasia (PIN)
and prostate cancer
It is widely accepted that PIN represents a precursor for
prostate cancer, although this relationship has not been
demonstrated conclusively (Bostwick 1989; DeMarzo et al.
2003). PIN is generally characterized at the histological
level by the appearance of luminal epithelial hyperplasia,
reductioninbasalcells,enlargementofnucleiandnucleoli,
cytoplasmic hyperchromasia, and nuclear atypia; in addi-
tion, high-grade PIN lesions generally display marked
elevation of cellular proliferation markers (Bostwick
1989;Shappelletal.2004).Incontrastwithprostatecancer,
however, basal cells are reduced in number in PIN, but are
not absent.
Although human prostate cancer displays significant
phenotypic heterogeneity, >95% of prostate cancers are
classified pathologically as adenocarcinoma, which has
a strikingly luminal phenotype (Fig. 2). In biopsy speci-
mens, prostate adenocarcinoma diagnosis can be con-
firmed by the absence of immunostaining using p63 and
cytokeratin 5/14 antibodies, both of which detect basal
cells (Humphrey 2007; Grisanzio and Signoretti 2008). In
addition, a diagnosis of prostate cancer is supported by
elevated immunostaining for a-methylacyl-CoA race-
mase (AMACR), a luminal marker that is overexpressed
in carcinoma (Luo et al. 2002; Jiang et al. 2005; Humphrey
2007). Similarly, prostate cancer arising in many mouse
modelsdisplaysarelativelyluminalphenotype(Kimetal.
2002d; X Ma et al. 2005). However, the overt histological
appearance of prostate carcinoma in most genetically
engineered mouse models often differs from that of
typical human prostate cancer (Fig. 2).
Subtypes of prostate cancer
A notable difference between prostate cancer and other
epithelial tumors, such as breast cancer, is the lack of
distinguishable histopathological subtypes that differ in
their prognosis or treatment response. The vast majority
of prostate cancers correspond to acinar adenocarcinomas
that express AR, while other categories of prostate
cancer—such as ductal adenocarcinoma, mucinous car-
cinoma, and signet ring carcinoma—are extremely rare
Figure 1. Progression pathway for human prostate cancer. Stages of progression are shown, together with molecular processes and
genes/pathways that are likely to be significant at each stage. Adapted from Abate-Shen and Shen (2000).
Figure 2. Histopathology of human and mouse
prostate cancer. (A–D) Hematoxylin-eosin-stained
sections of human prostate. (A) Benign normal
tissue, with representative basal (bas) and luminal
(lum) cells indicated. (B) PIN; arrows indicate
regions of hyperplastic epithelium. (C) Well-dif-
ferentiated adenocarcinoma. (D) Poorly differenti-
ated adenocarcinoma. (E–H) Hematoxylin-eosin-
stained sections of anterior prostate from geneti-
cally engineered mouse models. (E) Normal
tissue, with characteristic papillary tufting (arrow-
heads). (F) High-grade PIN. (G) Prostate carci-
noma. (H) Prostate carcinoma with an invasive phenotype. We thank Dr. Robert Cardiff and Alexander Borowsky (School of Medicine,
University of California at Davis) for providing images of human prostate specimens.
Shen and Abate-Shen
1970 GENES & DEVELOPMENT
Figure  1.1.1  Stages  of  human  prostate  cancer  progerssion.  Adopted 
from Abate-Shen and Shen (2000)    
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in the bone marrow and peripheral blood (Pantel and Alix-Panabieres, 2010). 
However, disseminated tumour cells were also found in patients with localised 
disease, which suggests the limited capability to metastasise at the early stage 
of  the  disease.  Yet,  the  circulating  tumour  cells  within  metastatic  disease 
consisted  of  multiple  chromosomal  rearrangements  comparable  with  typical 
advanced PC (Attard et al., 2009, Holcomb et al., 2008, Leversha et al., 2009). 
Despite the clinical importance of tumour metastasis, the molecular mechanisms 
involved in promoting this process remains to be resolved. Furthermore, recent 
genomic analysis (Taylor et al., 2010) have provided a great deal of insight into 
the molecular signature of PC, which allows us to distinguish subtypes of PC and 
stratification  of  patients  according  to  gene  expression  and  copy  number 
alteration.  
1.1.3 Mouse model of prostate cancer 
Mouse  models  have  provided  an  extremely  useful  research  platform  to 
study PC including, xenograft, tissue reconstitution and genetically engineered 
models. In vivo PC studies are often carried out by implanting human PC cell 
lines in immunodeficient mice orthotopically or transplanting into the flank. The 
xenograft  models  provided  a  great  insight  into  the  molecular  mechanisms 
involved in carcinogenesis and chemotherapeutic strategies. However there are 
major  limitations  to  the  xenograft  models,  notably  the  absence  of  a 
heterologous  microenvironment  associated  with  PC;  inability  to  analyse  the 
effect of the immune system and the restriction to using clonal cell lines. In 
order to manipulate specific genes in both mouse and human prostate tissue, 
tissue  reconstitution  models  are  employed  to  investigate  not  only  prostate 
organogenesis but also prostate tumorigenesis in vivo. This procedure often uses 
immortalised human or mouse prostate cells, which can reconstitute relatively 
normal (histology) prostate tissue. The gene of interest can be overexpressed or 
knocked down in vitro, and the subsequent phenotypes in vivo analysed. Such 
methods also allow us to study stromal compartments using cancer associated 
fibroblasts, and assess genes that give lethal embryonic phenotypes.  
Development  of  transgenic  mouse  models  for  prostate  cancer  has 
provided another useful approach to investigate prostate tumorigenesis and to 
recapitulate  human  disease.  To  date,  there  are  a  handful  of  genetically  
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engineered  mouse  models  for  PC.  The  first  transgenic  PC  mouse  model  was 
generated by Greenberg using potent viral oncogenes (Greenberg et al., 1995). 
The TRAMP (transgenic adenocarcinoma of the prostate) mouse model developed 
an  aggressive  disease  with  neuroendocrine  differentiation,  which  however  is 
rarely  observed  in  human  PC  (Shappell  et  al.,  2004).  Nonetheless,  the  first-
generation  of  transgenic  mouse  model  provided  important  insight  into  the 
disease progression and investigation of castration resistant disease. In order to 
target  specifically  prostate  tissue,  probasin  and  PSA  promoters  were  used  to 
drive candidate gene expression. The application of such approach to loss-of-
function mutations in the genes of interest has led to the second-generation of 
mouse models. There are few popular choices of models including Nkx3.1, Pten, 
Pb-Cre4, and Nkx3.1-Cre transgenes.  
Nkx 3.1 is a homeobox gene, which is shown to be involved in prostatic 
epithelial  development  and  differentiation.  Loss  of  Nkx3.1  gene  leads  to 
hyperplastic lesions in anterior, dorsolateral prostate and stroma regions, but 
the ventral prostate appears to be normal in 1-2 year old mouse model. Also in 
prostate  cell  lines  including  PC3  and  AT6  was  observed  decreased  cell 
proliferation when Nkx3.1 was overexpressed (Sciavolino et al., 1997, Kim et al., 
2002a, Kim et al., 2002b). This suggested that the Nkx3.1 gene has a potential 
tumour suppressive role. Both loss of Nkx 3.1 gene and epigenetic silencing of 
the gene have been detected in human prostate cancer (Emmert-Buck et al., 
1995, Voeller et al., 1997). However, the homozygous deletion of Nkx3.1 seems 
to  only  develop  PIN  phenotype  with  few  layered  epithelium  and  enlarged 
nucleoli  but  not  extreme  pleomorphism,  and  never  progress  into 
adenocarcinoma  or  metastatic  disease.  Given  PC  is  a  multistep  process, 
combination  of  candidate  tumour  suppressor  genes  and  oncogenes  in  mouse 
models have provided great insight into the molecular mechanisms involved in 
prostate  carcinogenesis.  Pten  is  one  of  the  most  commonly  mutated  tumour 
suppressor genes in human cancer, and Pten heterozygous mutant mice develop 
high grade PIN with incomplete penetrance, and the phenotype is closely related 
to the subtle Pten dosage in the mouse model (Carracedo et al., 2011b). Kim and 
his colleagues further investigated the cooperation of Nkx3.1 and Pten in mouse 
prostate. The double homozygous mutants displayed localised severe dysplastic 
lesions with higher penetrance in comparison with single mutant Pten or Nkx3.1  
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heterozygous  mice.  However,  there  was  no  difference  in  survival  profile 
between double and single mutants. High-grade PIN was observed with Nkx3.1
-/-; 
Pten
+/-  prostates.  This  suggests  the  cooperation  of  tissue  specific  genes  and 
common tumour suppressor genes can contribute to the tissue specific cancer 
progression.  Furthermore,  Tomlins  and  his  colleagues  discovered  for  the  first 
time  recurrent  chromosomal  rearrangement  in  human  prostate  cancer,  which 
involves two ETS transcription factors (ERG and ETV1) and 5’ untranslated region 
of  TMPRSS2  (Tomlins  et  al.,  2005).  This  study  led  to  the  generation  of  the 
TMPRSS2-ERG fusion mouse model, and the transgene positive mice developed 
dysplasia in prostate (King et al., 2009a). It suggested that such simple mutation 
might  not  sufficient  for  the  initiation  and  progression  of  the  PC.  However, 
combination  of  Pten
+/-  and  the  TMPRSS2-ERG  fusion  mice  developed  PIN  at  6 
months  with  invasive  phenotype,  suggesting  the  cooperation  between  PI3K 
signalling  pathway  and  ERG  in  the  PIN  development.  Interestingly,  the 
combination of different gene sets have demonstrated the development of PIN in 
mouse  model,  but  these  events  alone  could  not  progress  into  aggressive 
malignancies observed in human prostate. Recent intergrated genomic analysis 
of  human  PC  suggests  that  additional  mutational  events  are  required  for  the 
development  of  prostate  carcinoma  in  preclinical  mouse  model.  Yet,  as  the 
complexity  of  mutations  increase  in  mouse  model,  the  accurate  analysis  and 
interpretation of mechanisms involved in the progression of the diseases become 
a great challenge.  
 
1.1.4 Molecular mechanisms of prostate cancer initiation and progression 
Recent progress in the genetically engineered mouse models and in vitro 
studies have significantly advanced our understanding of molecular mechanisms 
involved in prostate carcinogenesis. Patients with advanced PC are often treated 
with  androgen  deprivation  therapy,  which  is  performed  either  with  the 
administration of drug using anti-androgens including bicalutamide, or surgical 
castration. AR plays a critical role in normal prostate development as well as 
prostate carcinogenesis. The Leydig cells within the testis synthesise the ligand 
testosterone acting as androgen, which is converted into its more active form 
dihydrotestosterone  in  prostatic  cells.  AR  is  a  member  of  steroid  nucleus  
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receptor,  and  acts  as  a  transcription  factor  upon  ligand  binding.  The  best 
characterised and clinically implicated AR target gene is KLK3, which encodes 
PSA protein. The androgen depletion therapy initially leads to rapid regression of 
androgen-dependent  prostate  tissue  via  apoptosis,  which  is  also  induced  by 
stromal  tissue.  The  function  of  stroma  was  evident  in  tissue  reconstitution 
experiments  with  androgen  dependent  cell  lines,  which  undergo  apoptosis 
following withdrawal of androgen. These cell lines showed reduced proliferation 
when androgen was not present, but not apoptosis when grown without stromal 
components  (Gao  et  al.,  2001,  Kurita  et  al.,  2001).  Due  to  the  selection 
pressure, PC eventually develops into a castration resistant state, which may 
involve  AR  mutation  or  increase  in  androgen  synthesis.  Castration  resistant 
tumour  cells  employ  various  interesting  ways  to  adapt  and  survive  in  AR 
withdrawn  environment.  The  most  common  AR  reactivation  mechanisms  are 
amplication/overexpression of AR, constitutively activating mutation, aberrant 
post-translational  modification,  and  alternative  splicing.  For  instance, 
approximately  over  30%  patients  with  castration-resistant  disease  show 
amplification  of  AR  genes  (Linja  et  al.,  2001).  Another  common  mechanism 
found  in  PC  patients  consists  of  gain  of  function  mutation  leading  to  more 
stable,  greater  sensitivity  to  the  ligands  or  constitutive  activation  of  the 
receptor with alternative splicing variant (Guo et al., 2009, Steinkamp et al., 
2009, Brooke et al., 2008). 
Another  receptor  family  including  ErbB  is  shown  to  interact  with  AR 
signalling  cascade  and  stimulate  prostate  cancer  cell  survival.  ErbB  family 
members consist of ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4), 
which are essential for developmental process and tumour progression. Although 
there are no mutations of ErbB receptors identified in prostate cancer, crosstalk 
between  AR  and  ErbB  signalling  and  contribution  to  castration  resistant  PC 
progression  was  reported  in  recent  years.  EGFR  and  ErB2  expression  was 
controlled by AR c-terminal domain and RTK are essential for cell proliferation in 
PC cell lines (Pignon et al., 2009). ErbB2 is also implicated in castration resistant 
PC through AR dependent DNA binding and its stablisation (Mellinghoff et al., 
2004).  Given  the  important  role  of  ErbB  signalling  in  PC  progression  and  the 
successful  outcome  in  targeting  ErbB  as  treatment  for  breast  cancer,  various 
chemotherapies against EGFR and HER2 were tested in preclinical models and PC  
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patients.  Currently,  there  are  several  tyrosine  kinase  inhibitors  (TKI)  and 
monoclonal antibodies developed for clinical trials, these include HER2-directed 
antibody  trastuzumab,  EGFR  inhibitors  (erlotinib  and  gefitinib)  and  EGFR-
directed monoclonal antibodies (cetuximab and panitumumab). Despite report of 
these TKI and monoclonal antibodies inhibiting cell proliferation in vitro and in 
xenograft models (Tomlins et al., 2005), phase II clinical trials on patients with 
advanced PC indicated no significant effect neither in PSA levels nor survival 
benefit (Gross et al., 2007, Morris et al., 2002, Salzberg et al., 2007). These 
disappointing  results  can  be  explained  by  the  effect  of  the  redundant  ErbB 
family members and their complex signalling network. Also RTK amplication does 
not occur as often as in breast and lung cancer.  
PTEN  (phosphatase  and  tensin  homolog  located  on  chromosome10)  is 
among  the  most  frequently  mutated  or  deleted  tumour  suppressor  genes  in 
human cancers, and was first identified in breast and PC (Li et al., 1997, Steck 
et  al.,  1997).  PTEN  is  encoded  on  chromosome  10q23,  and  consists  of  a 
phosphatase domain, C2 or lipid membrane-binding domain, C-terminal region 
and  PDZ-binding  domain  (Figure  1.1.2).    PTEN  is  well  known  for  its  negative 
regulatory role in PI3K/AKT signalling pathways via dephosphorlation of the 3-
phosphoinositide. The PI3K/AKT pathway is an important regulator of cell growth 
and  survival.  The  exact  status  of  PTEN  deregulation  in  PC  was  unclear  until 
recent multiple research approaches. The main questions were whether PTEN 
alleles were both deleted or only one allele is lost and the other one is mutated, 
or the expression is affected. After a long-standing debate, it is accepted that 
PTEN  undergoes  copy  number  loss  at  the  early  stage  of  carcinogenesis,  and 
complete  loss  of  PTEN  occurs  at  a  relatively  late  stage  of  PC  progression, 
including  aggressive,  and  castration-resistant  disease  (Taylor  et  al.,  2010). 
Pandolfi and colleagues asked an intriguing question regarding the relationship 
between subtle PTEN expression level and cancer susceptibility (Carracedo et 
al.,  2011a).  It  is  well  known  that  a  complete  loss  of  PTEN  bypass  cellular 
senescence  in  prostate  mouse  model,  and  becomes  a  hallmark  of  advanced 
human  PC.  The  PC  genomic  cBio  portal  showed  that  only  7%  of  PC  patients 
harboured complete loss of PTEN, which means the majority of cases still retain 
normal or low PTEN expression level (Taylor et al., 2010).  
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Indeed, it is important to address the importance of subtle reduction of 
PTEN in prostate carcinogenesis and other tumours. Interestingly, hypomorphic 
PTEN  mouse  model  with  PTEN  expression  level  between  heterozygous  and 
knockout resulted in a full penetrance PC with invasive phenotype (Trotman et 
al., 2003b). Furthermore, there are also other tumour suppressor genes, which 
exert their inhibitory function through PTEN, including Sprouty family members 
(Edwin et al., 2006). This suggests an interesting idea that subtle PTEN reduction 
can  have  a  dramatic  impact  in  carcinogenesis.  In  addition  to  the  membrane 
PTEN tumour suppressor role, recent reports suggest an interesting function of 
nuclear PTEN in cell cycle arrest, genomic instability, differentiation, and gene 
expression. In the nucleus, the phosphatase domain seems to not play a crucial 
role regarding nucleus PTEN enzymatic activities (Lindsay et al., 2006). On the 
basis  of  these  studies,  the  membrane  PTEN  is  merely  one  aspect  of  PTEN 
function in various cellular compartments.   
PTEN deficient PC results in abnormal activation of PI3K/AKT signalling 
pathway  (Thomas  et  al.,  2004).  The  canonical  PTEN/PI3K/AKT  pathway  is 
initiated from the activation of receptor tyrosine kinases (RTK), such as EGFR, 
and  ERBB2.  When  PTEN  expression  is  decreased  or  absent,  products  of  PI3K 
activates AKT via its upstream kinase PDK1 in an uncontrolled manner. There are 
many downstream targets for AKT including GSK3, p27, p21, mTOR and FOXO, 
which  are  responsible  for  cell  cycle  progression,  invasion  and  proliferation. 
mTOR also activates AKT in reciprocal feedback loop in PTEN deficient cancer 
cells.  Given  the  importance  of  PTEN/PI3K/AKT  signalling  pathway,  there  are 
many candidate drugs developed to target mTOR or PI3K or as dual inhibitors. 
However,  tumour  cells  evolve  to  adopt  other  kinase  signalling  pathways, 
including  MAPK  cascades,  and  consequently  resulting  in  more  aggressive  drug 
resistant disease. Using combinatory therapy to target such parallel networks 
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phosphorylation, ubiquitylation, oxidation, acetylation, 
proteosomal degradation and subcellular localization 
(reviewed in REFS 34,35). Although many of these post-
translational changes in PTEN have been shown to alter 
various cellular phenotypes in vitro, most have not been 
validated as key regulators of PTEN in human cancer 
or mouse models. PTEN amino acids Lys13 and Lys289 
are monoubiquitylated, which leads to nuclear import 
in vitro, and Lys289 mutations have been observed in 
Cowden syndrome and associated with nuclear exclu-
sion36. No Lys289 mutations have been reported in 
sporadic cancers, although Lys13 mutation was found 
in four of 632 endometrial cancers (see the COSMIC 
database; see Further information).
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Germline PTEN mutation in Cowden syndrome can 
lead to decreased or absent expression or activity of the 
mutant allele. Initial efforts to model Cowden syndrome 
in mice used genetic deletion of a single allele of Pten, as 
loss of both alleles is embryonic lethal. These Pten   
heterozygous (Pten+/–) mice recapitulated some of 
the neoplastic phenotypes observed in patients with 
Cowden syndrome, such as breast and endometrial 
tumours and intestinal polyps37–39. However, the genetic 
background of Pten+/– mice is a strong determinant of 
susceptibility to specific tumour types (BOX 1). Some 
strains exhibit tumour types that are not typically asso-
ciated with Cowden syndrome, such as prostate and 
adrenal tumours and lymphoma40, whereas other strains 
show a reduced incidence of tumours types that are nor-
mally associated with Cowden syndrome, such as breast 
and endometrial tumours41. Decreasing PTEN dosage 
has been shown to correlate with increasing tumour   
formation in mice, supporting the value of Pten+/– mice 
as models for Cowden syndrome.
Somatic PTEN alteration is common in many 
sporadic tumour types42, some of which also occur 
with germline PTEN alteration in Cowden syndrome 
(TABLE 1). This suggests that PTEN alteration may be an 
aetiological factor in these tumour types. Various tissue-
specific and/or inducible homozygous deletions of Pten 
have been generated in mice to model sporadic PTEN 
loss in tumorigenesis. In the endometrium43, mammary 
gland44 and prostate45, and in T cells46, homozygous dele-
tion of Pten led to rapid tumour formation in the tar-
geted tissue. Tumours took longer to develop after Pten 
deletion in the liver47, bladder48 and lung49. By contrast, 
when Pten was deleted in pancreatic  -cells50 or the 
intestine51, no malignant tumours developed, although 
intestinal polyps were common, as observed in Cowden 
syndrome. Loss of other tumour suppressors or the 
activation of oncogenes can nonetheless combine with 
PTEN loss to cause cancer in these organs. The follow-
ing sections describe the intersection of PHTS, sporadic 
cancer and mouse models to delineate the role of PTEN 
alteration in specific cancers.
Breast cancer. Female patients with Cowden syndrome 
have a high risk (an estimated 25–50% risk) of developing 
breast cancer over the course of their lifetime, and male 
patients with Cowden syndrome are also thought to be 
at an increased risk52. PTEN loss can also occur in other 
populations at a high risk of breast cancer, such as those 
that carry germline mutations in BRCA1 in which PTEN 
deletions have been described53, and can also occur in 
those at an indeterminate risk. For example, despite the 
fact that less than 5% of sporadic breast tumours har-
bour PTEN mutations, loss of PTEN immunoreactivity is 
observed in nearly 40%54. This highlights the importance 
of immunohistochemistry methodology in determining 
PTEN status55. Moreover, about 40% display loss of heter-
ozygosity (LOH) at 10q23 (REF. 56), and aberrant promoter 
methylation was identified in nearly 50% of tumours25.   
As PTEN loss and ERBB2 mutations both activate the 
AKT signalling pathway, perhaps it is not surprising that 
many tumours that exhibit loss of PTEN are also oestrogen 
receptor (ER)-positive and ERBB2-negative54.
Pten+/– mice can develop mammary tumours at high 
frequencies depending on their genetic background39. 
Deletion of both Pten alleles in the mammary epithe-
lium leads to altered mammary development and high-
frequency, early-onset tumours in mice44. Loss of a single 
Pten allele accelerated tumorigenesis in a Wnt-induced 
mammary tumour model, and most tumours lost the 
remaining Pten allele57. Similar results were observed 
when breast-specific Pten deletion was coupled with 
overexpression of Erbb2 (REF. 58). In two other models, 
subtle decreases in PTEN expression increased the risk 
of tumour formation in the absence of any other intro-
duced mutations22,23. These mouse studies suggest that 
decreased PTEN expression leads to an increased risk of 
breast tumour formation. Attenuated PTEN expression 
by gene mutation, LOH or promoter methylation may 
indeed be a driving alteration in breast cancer, making 
PTEN signalling pathways or pathways downstream   
of PTEN potential targets for breast cancer therapy.
Endometrial cancer. The lifetime risk of endometrial 
cancer for patients with Cowden syndrome is estimated 
to be 5–10%52,59, and 35–50% of sporadic endometrial 
carcinomas have PTEN mutations (TABLE 1). Mutations 
in PTEN are also observed in endometrial hyperplasia, 
which is thought to be a precursor lesion for endometrial 
carcinoma60–62. Many endometrial tumours have short 
insertion or deletion frameshift mutations that are typical 
of microsatellite instability. In particular, PTEN frameshift 
mutations are observed in endometrial carcinomas that 
are associated with hereditary non-polyposis colon 
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Figure 1.1.2 Schematic of the PTEN protein. Adopted from Hollander, 
Blumenthal and Dennis (2011)    
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seemed more effective in a preclinical model with PTEN depletion and castration 
resistant PC (Gumerlock et al., 1997). 
Initially  recurrent  chromosomal  rearrangements  were  discovered  in 
haematological  and  mesenchymal  neoplasm  but  rarely  in  solid  tumours. 
However, recent studies identified that such events also occur in many epithelial 
cancers  including  PC.  For  instance,  Tomlins  (Tomlins  et  al.,  2005)  identified 
chromosomal rearrangement between the ETS family of transcription factors and 
TMPRSS2 gene, which creates TMPRSS2-ERG or TMPRSS2-ETV1 fusion genes in the 
majority  (79%)  of  prostate  cancer.  TMPRSS2  is  an  androgen  responsive  gene 
loacated on the chromosome 21q, which activates the ETS family transcription in 
the case of the fusion gene. The mechanisms for chromosomal rearrangement at 
these  loci  were  suggested  as  either  an  interstitial  deletion  or  unbalanced 
interchromosomal  translocation  (Iljin  et  al.,  2006,  Perner  et  al.,  2006).  In 
addition,  AR  signalling  cascade  was  shown  to  be  involved  in  DNA  damage  by 
recruiting  topoisomerase,  which  may  be  associated  with  chromosomal 
rearrangement at this site (Haffner et al., 2010). Recent genomic profiling and 
mouse model studies suggest that the functional effect of ETS family alone is 
moderate which lead to the development of a weak PIN phenotype (Tomlins et 
al., 2007). Addition of the PTEN deletion synergises with ETS to result in high 
grade PIN and carcinoma in mice (Carver et al., 2009, King et al., 2009b). Thus 
despite  the  identification  of  the  chromosomal  arrangement,  the  functional 
effect  remains  to  be  fully  elucidated.  The  fusion  genes  may  cooperate  with 
other oncogenic events to promote prostate carcinogenesis. 
The first proposal of cancer stem cell (CSC) model in myeloid leukemia by 
John Dicks and colleagues became a paradigm for later studies in solid tumour 
CSC nearly a decade ago (Lapidot et al., 1994). The CSC was firstly identified in 
breast  cancer  as  a  solid  tumour  model,  and  represents  a  distinct  population 
within the tumour (Visvader, 2009). CSC is generally defined as subsets of cells 
with self-renewal ability, which can produce many different types of cancer cells 
with more differentiated phenotype. Such ability may explain the heterogeneity 
of solid tumours particularly in PC. The origin of CSC is unclear may derive from 
the  normal  stem  cells  which  accumulate  mutations.  For  prostate  cancer  CSC 
field,  there  are  still  many  questions  to  be  answered.  It  is  believed  that  the  
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localisation of prostate stem cells in the tissue is highly relevant to the origin of 
the CSC (Lawson and Witte, 2007). A glandular organ, the prostate consists of 
anatomically distinct epithelial cells including basal cells forming the basement 
of each prostatic duct, neuroendocrine cells in the basement layer along with 
the basal cells, and luminal cells lining the ductal lumens above the basal cells. 
Wang and his colleagues first characterised a rare population of prostate CSC 
called  CARNs  (castration  resistant  Nkx3-1-expressing  cells)  in  an  elegantly 
designed  transgenic  mouse  model.  CARNs  represent  a  luminal  stem  cell 
population with bipotential and self-renewal in vivo, which generates high grade 
PIN with targeted PTEN loss (Wang et al., 2009). Yet, identification of prostate 
cancer cell-of-origin was reported with isolation of normal human prostate with 
basal  cell  characteristics,  which  is  transplanted  to  induce  adenocarcinoma 
formation with luminal phenotype in a reconstitution mouse model (Goldstein et 
al., 2010). Altogether, prostate cancer may involve distinct subtypes of CSC, and 
recent CSC models required PTEN deletion to progress into aggressive tumour. 
However  the  different  molecular  pathways  involved  in  lineage  progression  to 
prostate cancer initiation remains to be elucidated. 
1.2 Sprouty and cancer: history of discovery  
Over a decade ago, the Sprouty (SPRY) family was discovered in a genetic 
screen while investigating genes involved in tracheal branching in Drosophila, 
owing its name to the ability to prevent excessive airway branching (Hacohen et 
al., 1998). The Drosophila SPRY protein was shown to be a general antagonist of 
several different receptor tyrosine kinases (RTK) (Casci et al., 1999, Kramer et 
al.,  1999,  Reich  et  al.,  1999).  Subsequently,  multiple  orthologues  of  SPRY 
proteins have been identified in zebrafish, Xenopus, mouse, chicken and human 
(Chambers  and  Mason,  2000,  Furthauer  et  al.,  2001,  Minowada  et  al.,  1999). 
There are four unique spry genes identified in mammals to date. The mouse and 
human SPRY (SPRY 1-4) genes encode 32-34 kDa proteins that are considerably 
smaller in size than Drosophila SPRY (63 kDa) (Figure 1.2.1). The mammalian 
SPRY  family  members  consist  of  divergent  sequence  at  their  amino  termini, 
which  may  dictate  their  differential  functions.  The  conserved  cysteine-rich 
domain is located at the carboxyl terminus of all SPRY proteins, and outside of 
this  region  there  is  conserved  tyrosine  residues.  SPRY  proteins  interact  with  
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other  signalling  molecules  containing  Src-homology-2  (SH2)  domains  via  the 
conserved  tyrosine  residues  region.  SPRED  (SPRY-related  enabled/vasodilator-
stimulated phosphoprotein homology 1 domain containing) proteins are related 
to SPRY proteins structurally and functionally. So far three human, three mouse, 
two Xenopus and one Drosophila SPRED members have been described (DeMille 
et al., 1996, Kato et al., 2003, Sivak et al., 2005). SPRED family members consist 
of the C-terminal cysteine-rich Sprouty-related domain (SPR) shared with SPRY 
proteins, and an N-terminal Enabled/VASP homology 1 domain (EVH1) (Wakioka 
et al., 2001, Kato et al., 2003). 
 
Mammalian SPRY proteins are widely expressed in the developing embryo 
as well as in adult tissues. Some initial studies showed that expression of SPRY 
proteins were regulated by growth factors (Minowada et al., 1999, Tefft et al., 
1999, Chambers and Mason, 2000, Chambers et al., 2000, Su et al., 2002). Large-
scale gene analysis of both human and mouse transcriptomes, showed SPRY2 to 
be ubiquitously expressed, but the other isoforms are more limited to certain 
organs and tissues. For instance, SPRY3 is distributed only in brain and testis 
(Minowada  et  al.,  1999).  Given  the  prototype  member  of  SPRY  family  is  an 
antagonist  of  RTKs  in  Drosophila,  many  reports  suggested  the  involvement  of 
SPRY  members  in  various  cancer  types.  SPRY1  and  SPRY2  are  consistently  
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downregulated at mRNA and protein expression level in more than 90% breast 
cancer patient samples, acting as an inhibitory regulator of Ras/MAPK signalling 
pathway  (Lo  et  al.,  2004).  In  liver  cancer,  there  is  evidence  for  silencing  of 
SPRY2  but  not  SPRY1,  but  the  percentage  of  patients  with  low  expression  of 
SPRY2 is not as great as in breast cancer (Fong et al., 2006). This may due to the 
fact  that  abnormal  RTK  signalling  plays  a  pivotal  role  in  breast  cancer,  and 
emphasises  the  importance  of  SPRY  in  RTK  signalling  regulation  network  and 
tumorigenesis.  In  addition,  ectopically  expressed  SPRY2  in  a  non-small  lung 
cancer cell line and in vivo model reduced cell migration and proliferation via 
inhibition  of  Ras/MAPK  cascade,  suggesting  a  tumour  suppressive  role  in  lung 
cancer  (Sutterluty  et  al.,  2007).  However,  there  are  a  few  tumour  types 
including colon cancer and melanoma, where a controversial role for SPRY is 
suggested.  For  instance,  Spry  is  shown  to  be  upregulated  in  global  gene 
expression analysis of melanoma cell lines (Bloethner et al., 2005) (Table 1.1). 
Nonetheless,  SPRY2  knockdown  in  melanocytes  with  wild  type  BRAF  inhibited 
MAPK  signalling  cascade,  but  did  not  affect  mutant  BRAF  containing  cells 
(Tsavachidou et al., 2004). Interestingly, human colon adenocarcinoma consists 
of  high  expression  level  of  SPRY2  compared  with  normal  tissue,  and 
overexpression of SPRY2 even exacerbated cell proliferation and invasiveness in 
the  xenografts  and  orthotopic  models  respectively,  suggesting  oncogenic 
function  of  SPRY2  in  colon  cancer  (Holgren  et  al.,  2010).  Collectively,  these 
evidences  suggest  the  complexity  of  SPRY2  function  in  various  types  of 
carcinogenesis, and emphasise the context dependent nature of SPRY2 action. 
 
Table 1.1 Expression of SPRY2 in a number of cancer types 
Type	 ﾠof	 ﾠCancer	 ﾠ SPRY2	 ﾠlevel	 ﾠ Reference	 ﾠ
Breast	 ﾠCancer	 ﾠ 	 ﾠ (Lo	 ﾠet	 ﾠal.,	 ﾠ2004)	 ﾠ
Colon	 ﾠCancer	 ﾠ 	 ﾠ (Holgren	 ﾠet	 ﾠal.,	 ﾠ2010)	 ﾠ
Hepatocellular	 ﾠCarcinoma	 ﾠ 	 ﾠ (Fong	 ﾠet	 ﾠal.,	 ﾠ2006,	 ﾠLee	 ﾠet	 ﾠal.,	 ﾠ2008)	 ﾠ
Prostate	 ﾠCancer	 ﾠ 	 ﾠ (McKie	 ﾠet	 ﾠal.,	 ﾠ2005)	 ﾠ
Non-ﾭ‐small	 ﾠCell	 ﾠLung	 ﾠCancer	 ﾠ 	 ﾠ (Sutterluty	 ﾠet	 ﾠal.,	 ﾠ2007)	 ﾠ
Melanoma	 ﾠ 	 ﾠ (Bloethner	 ﾠet	 ﾠal.,	 ﾠ2005)	 ﾠ
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1.3 Function of SPRY2 
1.3.1 SPRY2 and growth factor signalling 
The precise mode of SPRY action is difficult to pinpoint, as the functional 
role of the SPRY isoforms in different growth factor pathways varies in a distinct 
cell and tissue dependent manner. Mammalian SPRY proteins are referred to as 
master of modulators of growth factor signalling, and for most RTK signalling 
cascades. For FGF signalling, all of the SPRY isoforms inhibit FGF-induced MAPK 
activation  to  varying  degrees  (Lao  et  al.,  2006,  Ozaki  et  al.,  2005).  Yet,  in 
response to EGF stimulation, SPRY2 acts as a positive enhancer and potentiates 
MAPK activation in some cell types (Egan et al., 2002, Fong et al., 2003, Rubin et 
al., 2003). 
Given  SPRY2  is  the  most  highly  conserved  isoforms  across  vertebrates; 
most research has been heavily focused on SPRY2 in order to elucidate SPRY 
mediated functions. The inhibitory role of SPRY2 was first studied in the FGFR 
signalling cascade. In response to FGF, activation of FGFR recruits downstream 
molecule Shp2, which binds to phosphorylated tyrosines on FRS2. Activation of 
the SOS-Grb2 complex facilitates the activation of membrane-located Ras and 
downstream  ERK  signalling  (Hadari  et  al.,  1998).  It  is  reported  that  SPRY2 
physically interacts with Grb2 adaptor protein, and results in disruption in the 
formation  of  adaptor  complexes  including  FRS2  and  SOS1,  consequently 
inhibiting Ras-Raf-MAPK signalling pathways as shown in the figure 1.3.1 (Lao et 
al., 2006, Martinez et al., 2007). The interaction between Grb2 and SPRY2 was 
attributed to the stronger inhibitory role of SPRY2 compared to its other family 
members SPRY1 and SPRY4, which are due to the weak binding of Grb2-SPRY1 
and SPRY4 only binds to SOS1 and not Grb2 (Ozaki et al., 2005). Interestingly, 
Martinez’s  work  showed  that  the  mutation  at  the  Grb2  binding  sites  did  not 
affect  the  inhibitory  role  of  SPRY2  in  FGFR  signalling,  contradicting  Lao  and 
colleagues’  findings  (Lao  et  al.,  2006).  The  major  differences  in  these  two 
studies are the duration of FGFR mediated MAPK activation (transient and stable 
ectopic FGFR transfection) and cell types, hence the inhibitory effect of SPRY2 
in FGF signalling may be considered as temporal and cell context dependent.   
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The impact of SPRY family members in VEGF signalling cascades are often 
implicated in aberrant angiogenesis during carcinogenesis. Upon stimulation of 
VEGFR, PLCγ (phospholipase C gamma) and PKC (protein kinase C) phosphorylate 
Raf1  which  in  turn  activates  MAPK  signalling  molecules  in  a  Ras  independent 
manner  (Takahashi  et  al.,  2001)  (Figure  1.3.1).  Consequently,  the  inhibitory 
action of SPRY is different from other RTK pathways. It is reported that SPRY4 
strongly interacts with Raf1 via its RBD (Raf1 binding domain) and subsequently 
disrupts Raf1 mediated MAPK signalling. Given all SPRY members consists of a 
RBD in their highly conserved C-terminus, it is expected that other SPRY isoforms 
may have similar inhibitory effects in VEGFR signalling pathways.  
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1.3.2 SPRY2 and EGF signalling 
For many years, SPRY2 was generally considered as a Ras-MAPK inhibitor 
in the RTK signalling cascade. However, recent studies challenged the traditional 
view  of  the  SPRY  function  particularly  in  EGFR  signalling  network.  The 
controversial view is that SPRY can potentiate MAPK signalling in EGF stimulated 
cells  with  cell  type  dependent  manner.  This  is  due  to  the  fact  that  EGFR 
signalling involves a more complex mechanism involved in the balance between 
trafficking and degradation of the receptor. Upon ligand stimulation, EGFR can 
be  rapidly  degraded  in  order  to  control  the  magnitude  of  the  signalling  via 
interaction with the E3 ubiquitin ligase c-Cbl. It is reported that SPRY2 competes 
with EGFR for the c-Cbl binding sites, which in turn prevents the degradation of 
the  receptor  and  enhances  EGFR  mediated  signalling  (Haglund  et  al.,  2005). 
Other  RTK  including  FGFR  is  also  degraded  by  c-Cbl,  but  SPRY2  does  not 
interfere with the interaction between FGFR and c-Cbl. How SPRY2 distinguishes 
between  EGFR  and  FGFR  remains  to  be  investigated.  Kim  and  his  colleagues 
described  that  overexpression  of  SPRY2  delays  EGFR  trafficking  to  late 
endosomes,  consequently  rather  potentiating  EGFR  mediated  ERK  activation 
(Kim  et  al.,  2007).  In  summary,  SPRY2  exerts  tight  spatial  and  temporal 
regulation in order to achieve signalling specificity. 
  
1.4 Regulation of SPRY gene expression and localisation 
Drosophila Spry gene expression is generally controlled by RTK mediated 
transcription.  It  was  first  reported  that  overexpression  of  Drosophila  FGFR 
otholog  (Branchless)  induced  expression  of  SPRY  (Hacohen  et  al.,  1998).  In 
mammalian cells, Spry2 and Spry4 expression are induced via activation of EGF, 
FGF  and  PDGF  mediated  MAPK  function,  but  FGF  and  PDGF  showed 
downregulation of Spry1 transcription (Gross et al., 2001, Impagnatiello et al., 
2001, Sasaki et al., 2001). Gene array analysis revealed Spry2 gene promoter 
contained FOXO binding elements, and SPRY2 expression level is associated with 
FOXO deletion in endothelial cells (Dejana et al., 2007b).   
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The  regulation  of  SPRY2  protein  is  achieved  by  a  balance  between  its 
degradation  and  synthesis.  Growth  factors  including  FGF,  EGF  and  VEGF 
stimulation leads to the induction of Spry gene transcription (Impagnatiello et 
al., 2001, Sasaki et al., 2001, Ozaki et al., 2001), which initiates the negative 
feedback in RTK signalling network. Many reports suggested the phosphorylation 
of serine or tyrosine residues of SPRY2 allows interaction with other regulatory 
molecules,  and  in  turn  affects  its  stability.  For  instance,  upon  EGF/FGF 
stimulation,  MAPK-interacting  kinase  1  (Mnk1)  phosphorylates  SPRY2  at  serine 
112  and  121  residues,  which  competes  with  tyrosine  phosphorylation  at  the 
conserved N-terminal. This protects SPRY2 from binding C-cbl, and enhances its 
stability  (DaSilva  et  al.,  2006).  In  addition  to  C-cbl  mediated  degradation,  a 
yeast two-hybrid screen revealed another E3 ubiquitin ligase interaction partner 
SIAH2,  which  binds  to  SPRY2  regardless  of  RTK  mediated  tyrosine 
phosphorylation (Nadeau et al., 2007). All together, SPRY2 as a key regulator of 
RTK is tightly regulated in a temporal manner both in transcription and post-
translational level.  
 
1.5 SPRY2 in prostate carcinogenesis  
As  mentioned  before,  loss  of  SPRY2  appears  to  be  a  common  event  in 
many  tumour  types,  particularly  in  prostate  cancer.  First  report  from  Kwabi-
Addo  showed  an  involvement  of  SPRY  family  member  SPRY1  in  prostate 
carcinogenesis  (Kwabi-Addo  et  al.,  2004).  The  prostate  cancer  TMA  (tissue 
microarray)  analysis  revealed  over  a  third  of  patients  showed  SPRY1 
downregulation compared to normal tissue. However, the result was debatable, 
as some prostate tumours showed upregulation of SPRY1. Also it is reported that 
SPRY2 expression is controlled by genomic methylation, particularly in prostate 
cancer. Patient TMA analysis showed that high-grade tumours (gleason score 3-5) 
had  less  SPRY2  mRNA  level  compared  to  benign  prostatic  hyperplasia  (BPH), 
indicating a potential tumour suppressor role of SPRY in prostate carcinogenesis 
(McKie et al., 2005). There is evidence of loss of heterozygosity (LOH), but with 
lower  incidence  than  epigenetic  silencing.  In  addition,  recent  cBio  Cancer 
Genomic Portal analysis showed 26% of cases (n=103) with down-regulation of  
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SPRY2,  with  no  case  of  mutation  or  copy  number  changes  in  Spry2  gene.  In 
metastatic PC cases (n=37), there were 14 cases that reduced SPRY2 expression. 
Furthermore, patients with low level of SPRY2 expression showed significantly 
poorer survival outcome compared with unaltered SPRY2 expression level (Figure 
1.5.1).  In  summary,  loss  of  SPRY2  is  an  important  event  in  prostate 
carcinogenesis.  However,  at  what  stage  SPRY2  loss  occurs  and  what  its 
functional impact is remain to be elucidated. 
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1.6 Aims of the project 
The aim of this study is to investigate the impact of SPRY2 loss in prostate 
carcinogenesis,  particularly  the  controversial  mechanism  involved  in  the 
crosstalk  between  SPRY2,  EGFR  and  PTEN/PI3K/AKT  signalling  networks  in 
advanced prostate cancer including the use of preclinical models. The functional 
impact of SPRY2 loss is described in prostate cancer cell lines and in vivo in a 
preclinical mouse model. The involvement of SPRY2 reduction in RTK signalling 
pathway  was  investigated  including  EGFR/HER2  trafficking  and  downstream 
signalling  cascades.  Given  the  important  function  of  SPRY2  loss  in  prostate 
cancer, we assessed targeted chemotherapeutic strategies in a Spry
+/- Pten
+/fl 
preclinical model. Finally the potential interaction partners of SPRY2 in prostate 
cancer cell lines are examined using SILAC proteomic technology 
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Chapter 2. Materials and Methods 
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2. Materials and Methods 
2.1 Materials 
All general laboratory reagents used in this study are listed in Table 2.1 
below. 
Table 2.1 General reagents 
Reagent  Source 
Ampicillin  Sigma 
BSA (bovine serum albumin)  Sigma 
DAPI (4',6-diamidino-2-phenylindole)  Vector 
DMEM (Dulbecco's Modified Eagle's 
Medium)  GIBCO 
DMSO (dimethyl sulfoxide)  Fisher Scientific 
ECL (enhanced chemiluminescence)  GE healthcare 
Ethanol  Sigma 
F12  GIBCO 
FBS (fetal bovine serum)  PAA 
kanamycin  Sigma 
L-glutamine  GIBCO 
Lipofectamine 2000  Invitrogen 
Matrigel  Invitrogen 
Methanol  Sigma 
MOPS SDS running buffer (20x)  Invitrogen 
NaCl  Sigma 
Nitrolcellulose membranes  Fisher Scientific 
Penicillin Streptomycin  GIBCO 
PFA (paraformaldehyde)  Science Services 
Phosphatase inhibitors cocktail  Thermo Scientific 
Protease inhibitors cocktail  Thermo Scientific 
RPMI-1640  GIBCO 
SimplyBlue Safestain  Invitrogen 
Tris-HCl  Sigma 
Triton X-100  Sigma 
Trypsin  GIBCO 
Tween-20  Sigma 
β-Mercaptoethanol  Sigma 
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All buffers and solutions used in the study are listed in Table 2.2. 
Table 2.2 Solutions and buffers 
Solution  Composition 
Phosphate Buffered Saline (PBS)  170 mM NaCl 
  3.3 mM KCl 
  1.8 mM Na2HPO4 
  10.6 mM KH2PO4 
   PH 7.4 
Tris-buffered saline - Tween (TBST)  25 mM Tris - HCl pH 7.4 
  137 mM NaCl 
  5 mM KCl 
   0.1% Tween - 20 
Immunoblotting buffer  192 mM glycine 
  25 mM Tris 
   20% methanol 
Lysis buffer  50 mM Tris - HCl pH7.5 
  150 mM NaCl 
  1% Triton 
   1 mM EDTA 
Fixing solution  4% PFA 
   96% PBS 
Blocking buffer (Immunoblotting)  5% w/v milk powder in 
TBS-T 
Blocking buffer 
(immunofluorescence)  10% FBS 
  1% w/v BSA 
   90% PBS 
Permeabilizing solution 
(immunofluorescence)  0.1% Triton X-100 in PBS 
Lysogeny broth (LB)  1% Bacto-tryptone 
  86 mM NaCl 
   0.5% yeast extract 
LB agar  1.5% agar 
Tris-EDTA (TE)  10 mM Tris-HCl pH 8.0 
   1 mM EDTA 
3x SDS-PAGE sample buffer  125 mM Tris pH 6.8 
  4% SDS 
  15% β-Mercaptoethanol 
  15% glycerol 
   0.01% bromophenol blue 
Citrate buffer PH6  10 mM sodium citrate 
   0.05% Tween 20 
Tris-buffered Saline (TBS)  25 mM Tris - HCl pH 7.4 
  137 mM NaCl 
   5 mM KCl  
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2.2 Methods 
2.2.1 Cells and Growth Condition 
Human prostate cancer cell lines DU145, PC3, LNCaP and CWR-22 were 
authenticated  by  LCG  standards  and  purchased  from  ATCC.  These  cells  were 
grown  in  RPMI  (Gibco)  containing  10%  fetal  bovine  serum  (FBS)  and  2mM  L-
Glutamine  (GIBCO)  at  sub-confluent  conditions.  Cells  were  maintained  as 
described previously (Masters and Stacey, 2007). Briefly, cells were grown in a 
humidified incubator at 37°C in 5% CO2 and passaged every 3-4 days. Medium 
was aspirated and cells were washed with PBS once, followed by incubation with 
Trypsin (Invitrogen). Cells were collected and counted with CASY® cell counter 
(Innovatis) and seeded for maintenance. 
For long-term storage cell lines were cryo-frozen. Cells were trypsinised 
and  resuspended  in  50%  FBS,  40%  full  medium  and  10%  DMSO,  then  froze  in 
cryotubes (Nunc) at -80°C overnight and stored in liquid nitrogen. 
   
2.2.2 Cell Proliferation Assay 
Cells were seeded at a concentration of 5 x 10
3cells/well in 100 µl culture 
medium into microplates (tissue culture grade, 96-wells, flat bottom) (Becton 
Dickinson). After various treatments for 48 h at 37°C and 5% CO2 condition, 10µl 
Cell Proliferation Reagent WST-1 (Roche) was added and incubated for 30 mins. 
The  absorbance  of  the  samples  against  a  background  control  as  blank  was 
measured using a microplate (ELISA) reader. The wavelength for measuring the 
absorbance was 450nm and the reference wavelength was set at 650nm. 
2.2.3 Matrigel Invasion Assay 
For  the  invasion  assay,  the  24-well  configuration  of  the  BioCoat™ 
Matrigel™  Invasion  chambers  (BD  Sciences)  was  used.  The  matrigel  was 
rehydrated with warm serum free medium for 2h in a humidified tissue culture 
incubator.  After  incubation,  40,000  cells/well  were  seeded  in  triplicate  and  
    37 
allowed  to  invade  through  transwell  chambers  with  8  mm  pore  membranes 
coated with matrigel for 8 h with 10% serum or 20 ng/ml EGF (Invitrogen) as 
chemo-attractant. The chemo-attractant was added in the wells of a companion 
plate. After incubation, the non-invading cells were removed from the upper 
surface of the membrane using cotton buds. Cells that had invaded to the lower 
surface of the membrane were fixed in 100% methanol and the membrane was 
mounted onto slides. Invaded cells were stained with DAPI and visualised under 
microscope (Nikon). 
2.2.4 Receptor Internalisation Assay 
EGFR  internalisation  assays  were  performed  after  overnight  serum 
starvation  followed  by  EGF  (Invitrogen)  treatment  (20  ng/ml)  as  described 
previously (Sarto et al., 2007). Cells were coated with NHS-S-S-biotin (Sigma) 
before EGF treatment for 30 mins at 4°C with rocking, then cells were washed 2 
times with cold PBS. The cell surface biotin was reduced with cell impermeable 
MesNa (sodium 2-mercapto-ethanesulfonate) (Sigma) for 1 h with rocking at 4°C. 
The  reaction  was  stopped  with  reducing  agent  iodoacetamide  (Sigma).  Cells 
were washed with PBS 2 times, and WCL (whole cell lysate) were collected for 
either ELISA or IP (Immunoprecipitation) experiments. For ELISA detection, 96 
well plates were coated with EGFR antibody overnight and washed with PBST (5% 
BSA).  Internalisation  assays  were  performed  in  the  presence  of  0.6  mM  of 
primaquine (Sigma). For IP, the internalisation was performed and whole cell 
lysates were used to IP the biotin labelled EGFR with Dynabeads® (Invitrogen) or 
NeutrAvidin  (Thermo  Scientific)  instead  of  ELISA  plates.  Dynabeads®  were 
incubated with EGFR antibody (BD bioscience) for 1h at 4°C, and the beads were 
washed with lysis buffer 3 times before added to the WCL for IP. Proteins bound 
to the beads were eluted by boiling, and western blot analysis was performed.  
2.2.5 Immunoblotting 
Cells  were  lysed  with  lysis  buffer  containing  Halt  protease  inhibitor 
cocktail  (Thermo  Scientific)  and  Halt  phosphatase  inhibitor  cocktail  (Thermo 
Scientific) as described by the manufactures instruction. Briefly, the whole cell 
lysate  were  centrifuged  for  15  mins  at  13200  rpm,  and  the  supernatant  was 
collected for measurement of protein concentration. Bio-RAD Protein Assay (Bio- 
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RAD)  and  spectrophotometer  (595  nm)  was  used  for  determining  protein 
concentration.  All  the  protein  samples  were  adjusted  to  be  at  equal 
concentration  with  lysis  buffer.  Subsequently  the  samples  were  boiled  in  3x 
sample buffer for 10 min at 100°C and loaded in NuPAGE 4-12% Bis-Tris Gel 
(Invitrogen). The gels were electrophoresed in XCell SureLock Mini-Cell tank 
(Invitrogen) at 120mA and 200V in 1x MOPS SDS running buffer (Invitrogen).  
The  separated  proteins  were  transferred  from  the gel  to  nitrocellulose 
membrane using semi-dry western transfer in 1x transfer buffer. Each gel was 
transferred at 20 V and 200 mA for 1h. The membranes were blocked in 5% milk 
(Marvel)/TBST for 60 mins incubated with primary antibodies solution overnight 
at  4°C.  After  washing  with  3x  TBS-T  for  5  mins,  secondary  antibodies  were 
added in the blocking solution for 1h at room temperature. The antibodies used 
in  this  study  are  listed  in  Table  2.4.  The  proteins  on  the  membrane  were 
visualised by ECL detection kit (GE Healthcare). 
2.2.6 Transfection 
For generation of stable SPRY2 knock down cell lines, a 19mer sprouty2 
target sequenc (5’-AACACCAATGAGTACACAGAG-3’) (Qiagen) was used, and non-
silencing control sequence was obtained from Qiagen. Plasmid pTER+ were used 
to insert the sequence of interest, and stably expressed in DU145 and PC3 cell 
lines. The stable SPRY2 KD cell lines were generated by Dr Rachana Patel. For 
transient  SPRY2  siRNA  transfection,  two  different  siRNA  sequences  were 
purchased from Dharmacon, and PTEN siRNA was obtained from Cell Signalling. 
Transfection was carried out with Amaxa Cell Line Nucleofactor Kit (Lonza) as 
manufactors instruction.   
For IP and IF, plasmids were transfected into cells with Lipofectamine™ 
2000 (Invitrogen) following the manufacturer’s instructions. For 150 mm plate, 3 
µg of appropriate DNA plasmids were mixed with 1 ml serum free medium and 
20µl Lipofectamine™ 2000, and incubated at room temperature for 20 mins to 
allow  DNA-Lipofectamine™  2000  complexes  to  form.  After  incubation,  the 
mixture was added to the cells drop wise. Cells were incubated in humidified 
tissue culture incubator until ready to assay (24-48 h post transfection).  
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2.2.7 Immunofluorescence (IF)  
Cells were transfected with GFP-EEA1 vector (Addgene) for 24 h and fixed 
in 4% paraformaldehyde for 15 mins. Cells were permeabilised with 0.1% Triton 
X-100 (Sigma). Non-specific binding was blocked with a mixture of 10% FBS, 1% 
BSA and PBS. Then the blocking solution was removed and cells were incubated 
with  appropriate  primary  antibodies  for  1h  at  room  temperature.  Primary 
antibodies were diluted in 10% FBS, 1% BSA and PBS. Alexa Fluor® 555 and 488 
(Invitrogen) was used as secondary antibody, and the nucleus was stained with 
DAPI.  Simultaneous  dual  fluorescence  acquisitions  were  performed  using 
confocal microscope (Nikon) with 488 and 568 nm laser lines to visualise GFP and 
Texas red dyes using 60x oil immersion (scale bar 20µm).  
2.2.8 SILAC (stable isotope labelling with amino acids in cell culture) labelling 
Cells were grown in the medium containing appropriate stable isotopic 
amino acids reagents listed below for at least 5 passages. The whole cell lysates 
were  collected  and  tested  for  incorporation.    When  the  incorporation  rate 
reached above 90%, cells were used for IP experiments.  
Table 2.3 Stable isotopic amino acids used in SILAC media 
Stable 
isotopic 
amino acids 
Concentration 
in RPMI 
Mass 
difference 
Source  Combination 
L-lysine 2HCL  100mg/L  0Da  Sigma  Light 
L-Arginine HCl  100mg/L  0Da  Sigma  Light 
L-Lysine 2HCl 
(4,4,5,5-D4) 
100mg/L  4Da  Cambridge 
Isotope 
Medium 
L-Arginine 
(13C6) 
50mg/L  6Da  Cambridge 
Isotope 
Medium 
L-Lysine 2HCl 
(13C6, 15N2) 
100mg/L  8Da  Cambridge 
Isotope 
Heavy 
L-Arginine HCl 
(13C6, 15N4) 
50mg/L  10Da  Cambridge 
Isotope 
Heavy 
 
2.2.9 Immunoprecipitation (IP) 
Prior to harvesting the cells, they were transfected with GFP (Addgene) or 
GFP tagged SPRY2 plasmids for 48 h. GFP tagged SPRY2 plasmid was constructed  
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with inserting SPRY2 sequence into GFP plasmid. Cells were stimulated with 100 
ng/ml EGF after 24 h starvation. Cells were lysed in lysis buffer and the lysate 
was cleared by centrifugation at 13000 rpm for 15 min at 4°C. The whole cell 
lysates were incubated with GFP-Trap®_A beads (Chromotek) at 4°C for 1h with 
rotation. The beads were washed 3 times with lysis buffer and then boiled at 
100°C in 1% SDS to elute IP proteins bound to the beads. 
2.2.10 Animals 
All  animal  experiments  were  carried  out  under  the  UK  Home  Office 
guidelines (project licence 60/3947, and personal licenced 12870). Mice were of 
a mixed background and littermates were used as control mice. 
Nkx 3.1-Cre (Hsieh et al., 2010) mice were crossed to those harbouring 
Spry2
+/- (Shim et al., 2005) and Pten
fl/+ (Lesche et al., 2002).  The mice were 
genotyped  by  PCR  by  Transnetyx
TM  (Shim  et  al.,  2005,  Lesche  et  al.,  2002, 
Andrechek et al., 2000). Prostates were dissected out and placed in formalin for 
overnight fixation before paraffin embedding. 
PI 103 treatment was commenced when the prostate tumour was palpable 
in the mouse model (10-11 months). PI 103 was injected daily 50 mg/kg intra-
peritioneal  (ip)  for  4  weeks.  Prostate  tissues  were  collected  and  fixed  in 
formalin or frozen in liquid nitrogen for western analysis.  
2.2.11 Immunohistochemistry 
Tissue samples were formalin-fixed, paraffin-embedded, and stained for 
at least 3 samples from 3 different mice. The tissue sections were prepared in 
the histology services. For Ki67 staining, Ki67 antibody (Vector Labs) was used at 
1/100 dilution, and antigen unmasking was performed in citrate buffer (pH 6) 
and incubated for 50 mins at 99
oC in a water bath. For p-AKT (ser473) (Cell 
Signaling,  1/50  dilution)  and  pERK1/2  (Cell  Signaling,  1:100  dilution),  citrate 
buffer or Tris/EDTA buffer (pH8) and microwave antigen retrieval method was 
used. The antibodies are listed in the Table 2.4.  
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2.2.12 Tissue microarray analysis of human prostate cancer 
With ethical approval (MREC 01/0/36), formalin-fixed, paraffin-embedded 
(FFPE) sections from 239 patients were studied. These consisted of 209 primary 
prostate  carcinomas  (PC)  and  30  benign  prostatic  hyperplasia  (BPH)  samples. 
Three 0.6mm cores of prostate cancer tissue from each case were identified by 
pathologists  and  removed  from  representative  areas  of  the  FFPE  blocks.  All 
cancer samples had been taken from prostate cancer patients at the time of 
trans-urethral  resection  of  the  prostate  (TURP).  These  samples  consisted  of 
Gleason 3 (n=123), 4 (n=49) to 5 (n=37) cancers, as determined independently by 
two  consultant  pathologists  (MS  and  RJB).  These  samples  were  processed  by 
immunohistochemistry. Survival analysis was performed using Kaplan Meier plot 
and log rank test. 
2.2.13 Statistics 
All the statistical analysis was performed using Prism 5 software, and all 
graphs  were  generated  using  Microsoft  Excel  software.  The  error  bars  were 
calculated and represented in terms of mean ± SD. 
 
Table 2.4 List of antibodies used in this study 
Antigen  Supplier  Dilution 
Actin  Sigma; A4700  1:1000 
AKT  Cell Signaling; 9272  1:1000 
ATF2  Cell Signaling; 9226  1:1000 
BRaf  Cell Signaling; 9433  1:1000 
CKB  Abcam; ab38212  1:1000 
Clathrin  Cell Signaling; 4796  1:1000 
EGFR  Cell Signaling (western)  1:1000  
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Santa Cruz; sc103 (IHC) 
BD Bioscience (IP and IF) 
1:100 
1:!00 
ERK1/2  Cell Signaling; 9102  1:1000 
GAPDH  Sigma; G9295  1:12000 
GFP  Cell Signaling; 2956  1:1000 
HER2 
Cell Signaling; 8339 
(western) 
Cell signalling (IHC) 
1:1000 
1:100 
HER3  Cell Signaling; 8339  1:1000 
p-AKT 
Cell Signaling; 4060 
(western) 
Cell signalling (IHC) 
1:1000 
1:100 
p-ATF2  Cell Signaling; 9221  1:1000 
p-EGFR  Cell Signaling; 9922  1:1000 
p-ERK1/2 
Cell Signaling; 9101 
(western) 
Cell signaling (IHC) 
1:1000 
1:100 
p-HER2  Cell Signaling; 8339  1:1000 
p-HER3  Cell Signaling; 8339  1:1000 
p-p38  Cell Signaling; 9790  1:1000 
P38  Cell Signaling; 9790  1:1000 
PKM2  Cell Signaling; 3198  1:1000  
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PP2A  Cell Signaling; 2259  1:1000 
PTEN 
Cell Signaling; 9188 
(western) 
Cell Signaling (IHC) 
1:1000 
1:50 
SPRY2 
Abcam; ab50317 (IHC) 
Sigma; s1444 (western) 
1:50 
1:1000 
Tubulin  Sigma; T6557  1:2000 
FLAG  Sigma; F3165  1:100 
Anti-rabbit IgG, HRP-
linked Antibody  
Cell Sigmaling; 7074  1:5000 
Anti-mouse IgG, HRP-
linked Antibody 
Cell Signaling; 7076  1:5000 
 
Table 2.5 List of inhibitors used in this study 
Inhibitors  Suppliers  Dilutions 
Gefitinib  LC Laboratories; G4408  15 μM 
Lapatinib  LC Laboratories; L4804  10 μM 
SB203580  Sigma; s8307  10 μM 
PI103  Tocris Bioscience; 2930  50 mg/kg 
LY294002  Sigma; L9908  10 μM 
Dynasore  Sigma; D7693  5 μM 
PD098059  Sigma; p215  10 μM 
 
  
    44 
Chapter  3.  Functional  contribution  of  SPRY2  in 
human PC cells and a preclinical mouse model 
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3  Functional  contribution  of  SPRY2  in  PC  cell  line  and 
preclinical mouse model 
In prostate cancer, work from our laboratory has previously showed that 
SPRY2,  one  of  mammalian  SPRY  orthologues  (SPRY  1-4),  is  epigenetically 
silenced in almost 70% of primary prostate cancer (McKie et al., 2005). SPRY2 
physically  interacts  with  several  adaptor/regulator  proteins  downstream  of 
RTKs, including PP2A, Grb2, Braf, Shp2, c-Cbl and GAP1 (Danese et al., 2007). 
The large number of binding partners for SPRY2 is consistent with its crucial yet 
complicated  role  in  RTK  signalling.  Indeed,  whether  SPRY2  functions  as  a 
positive or negative regulator in EGFR signalling network remains an important 
question.  In  addition  to  its  well-reported  function  as  an  inhibitor  of 
RAS/RAF/MEK signalling cascade (Bordoni et al., 2007), Edwin and his colleagues 
reported  that  SPRY2  exerts  its  inhibitory  role  in  PI3K/AKT  signalling  pathway 
through  PTEN,  by  enhancing  its  activation  and  stability  (Edwin  et  al.,  2006). 
PTEN is among the most commonly mutated genes in human cancer, including 
prostate cancer. Progressive inactivation or loss of PTEN appears to be involved 
in  development  of  invasive  and  metastatic  PC.  Transgenic  mice  with  PTEN 
heterozygous deletion targeted to the prostate develop high-grade PIN, which 
fails to progress into invasive phenotype (Mellinghoff et al., 2004). Furthermore, 
complete loss of PTEN is thought to be a late event and can be considered a 
critical landmark for progression to aggressive and invasive disease. Indeed, the 
Pten  null  murine  prostate  cancer  model  developed  invasive  adenocarcinoma 
(Song et al., 2011). This is consistent with the cBio portal data, which revealed 
~24% (25/104) of PC retains PTEN expression albeit at low levels and only ~7% 
(7/104)  of  PC  showed  evidence  of  homozygous  Pten  deletion  (cBio  Cancer 
Genomics Portal) (Taylor et al., 2010). It is worth noting that as many as 50% 
(17/37) of metastatic tumours harboured biallelic Pten loss. 
To date, functional studies of SPRY2 have studied effects of transiently or 
stably  over-expressed  SPRY2  in  in  vitro  cell  models  (Kawakami  et  al.,  2009, 
Rubin et al., 2003). As SPRY2 expression tends to be suppressed in cancer, we 
set out to investigate the significance of SPRY2 loss using human prostate cancer 
cell models with knocked down SPRY2 expression and a preclinical mouse model.  
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3.1  Analysis  of  SPRY2  expression  and  effect  of  SPRY2  loss  in 
prostate cancer cell lines 
In order to understand the effect of SPRY2 in prostate cancer progression, 
the  expression  of  SPRY2  was  examined  in  various  prostate  cancer  cell  lines, 
including PC3, PC3M, LNCAP, DU145, CWR22 and PNT-2A. The classic prostate 
cancer cell lines including PC3 and DU145 were obtained from a patient with 
metastatic PC, and PC3 cell line is generally considered having more invasive 
ability compared to DU145. DU145 is derived from a distant metastatic organ 
(brain)  in  a  PC  patient.  Among  these  cancer  cell  lines,  except  LNCAP  cells 
expression  of  SPRY2  is  detected  by  western  blot  analysis  (Figure  3.1.1). 
Considering the important role of PTEN in the function of SPRY2, PC3 and DU145 
cell lines were selected to further study the effect of SPRY2 loss, since they 
have PTEN null and positive background respectively. 
 
 
Stable  knockdown  of  SPRY2  clones  of  prostate  cancer  cell  line  DU145 
(CL13 and CL61) and PC3 (CL1 and CL10) along with non-silencing control (Nsi) 
cells  were  generated.  Western  blot  analysis  confirmed  reduction  of  SPRY2 
expression  in  knockdown  clones  (Figure  3.1.2).  Due  to  the  difference  in  the 
shRNA  sequence,  the  knockdown  effect  was  expected  to  be  different; 
consequently the impact of the two shRNA in SPRY2 KD clones may vary. The  
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effect  of  SPRY2  KD  in  DU145  and  PC3  were  examined  in  response  to  EGF 
stimulation. Upon the ligand binding, DU145 SPRY2 KD clones 13 and 61 showed 
significantly  more  EGF  mediated  proliferation  compared  to  the  Nsi  control. 
However, PC3 cells did not show any difference in cell growth between SPRY2 KD 
clones and control cells (Figure 3.1.2). Such difference may be attributed to the 
PTEN status in these cells. It is reported that presence of PTEN is essential for 
SPRY2 to act as an inhibitory regulator in RTK signalling cascades, particularly in 
cell proliferation (Edwin et al., 2006). In addition, matrigel plug was used to test 
the invasiveness of SPRY2 KD cells. The PTEN positive DU145 cells with reduced 
SPRY2  expression  showed  over  40%  more  cells  invading  through  the  matrigel 
towards to the chemoattractant EGF when compared to Nsi control cells. The 
number of invading SPRY2 KD cells were visualised with DAPI staining and were 
more than 2 fold higher than that observed for Nsi control cells. Interestingly, 
loss of SPRY2 in PC3 cells decreased the invasiveness in response to EGF (Figure 
3.1.3). We reasoned the difference in proliferation and invasiveness in PC3 and 
DU145 with loss of SPRY2 may be attributed to the level of PTEN expression.  
In order to investigate the functional effects of PTEN in relation to SPRY2 
expression status, we used siRNA to transiently KD PTEN in DU145 Nsi and SPRY2 
KD cells. Western blot analysis showed the reduction of PTEN expression with 
the  siRNA  transfection  but  not  with  the  control  scramble  siRNA  treated  cells 
(Figure 3.1.4). Consistent with my hypothesis, the concomitant loss of SPRY2 and 
PTEN expression in DU145 cells led to one-fifth reduction in invasion, and there 
was no alteration observed in cell growth. Furthermore, there were increases 
both  in  cell  growth  and  invasion  in  Du  Nsi  cells  with  PTEN  siRNA  tranfection 
(Figure 3.1.4). Reduction in PTEN level may release the inhibition of PI3K/AKT 
signalling pathways, which leads to the increase in proliferation and invasion in 
Nsi cells. Overall, loss of SPRY2 cooperates with EGF stimulation, and enhances 
cell proliferation and invasion in PTEN-dependent manner. 
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3.2  Loss  of  SPRY2  enhances  the  activation  of  EGFR  signalling 
pathways upon EGF stimulation 
Downstream signalling following EGF stimulation in SPRY2 KD DU145 cells 
was examined using the Human Phospho-Kinase Array. Cells were serum starved 
overnight and stimulated with EGF for 15 minutes. Among the 46 phospho-kinase 
profile, PI3K/AKT and MAPK were key pathways activated upon EGF stimulation. 
Interestingly,  we  only  observed  a  difference  (20%)  in  AKT  phosphorylation  at 
serine 473, but not threonine 308. Activation of PI3K/AKT can lead to elevation 
of JNK phosphorylation, which contributes to prostate tumour cell proliferation 
and  angiogenesis  (Slack  et  al.,  2005).  Downstream  signalling  components  of 
PI3K/AKT  and  MAPK  such  as  JNK  and  c-Jun  also  showed  higher  level  of 
phosphorylation in SPRY2 KD cells. Since DU145 cells have amplification of Ras, 
and  an  inhibitory  effect  of  SPRY2  in  Ras-MEK-ERK,  both  MEK1/2  and  its 
downstream ERK1/2 are activated. We also observed enhanced activation of the 
stress MAP kinase p38 in SPRY2 KD cells by EGF (Figure 3.2.1). For p-P38 signal, 
the membrane was exposed slightly longer to detect the difference, it may be 
due  to  the  sensitivity  of  p-P38  antibody  in  the  assay  kit  or  the  amount  of 
phosphorylated form of P38 is relatively less compared to other proteins (Figure 
3.2.2). Some of the above findings were confirmed in Western blot following 15 
and 30 minutes of EGF stimulation. As we expected, the PTEN null PC3 cells 
showed less activated level of p-AKT in SPRY2 KD cells compared to Nsi control 
cells  (Figure  3.2.3).  Thus  there  were  no  significant  difference  in  increase  of 
proliferation and invasiveness in SPRY2 KD PC3 cells compared to the Nsi control 
cells, which were observed in Chapter 3.1. Together, loss of SPRY2 activates 
PI3K/AKT signalling cascade, which is a key component for the EGF driven cell 
growth and invasion.  
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3.3 Loss of SPRY2 and PTEN in a preclinical mouse model 
The preclinical mouse model for prostate cancer is often studied using a 
conditional gene knockout (KO) method, which allows the functional analysis of 
the gene of interest. One of the common systems is the Cre loxP recombination 
system, which gives tissue specific gene alterations (Nagy, 2000). The technology 
works  as  follows:  loxP  sequence  flanks  the  specific  gene,  and  upon  Cre 
recombinase  expression  the  target  gene  is  deleted  through  recombination 
between  loxP  sites.  For  the  prostate,  the  organ  specific  deletion  is  often 
achieved with the Pb-Cre4 or Nkx3.1-Cre mediated strategies (Trotman et al., 
2003a).  Nkx  Cre  driven  recombination  occurs  in  the  prostate  epithelium,  and 
also affects other organs during development (Thomsen et al., 2008, Zhang et 
al., 2008). Given the critical tumour suppressor role of PTEN, there are several 
reports on PTEN deletion in PC mouse model. Germline deletion of one Pten 
allele  developed  PIN  and  high  grade  PIN,  but  no  adenocarcinoma  or  invasive 
prostate cancer was observed (Podsypanina et al., 1999, Di Cristofano et al., 
1998).  In  addition  more  aggressive  adenocarcinoma  of  prostate  was  observed 
when combinations of other oncogenic genes were engineered to cooperate with 
PTEN including c-Myc, p53, TMPRSS-ERG fusion (Carver et al., 2009, King et al., 
2009b, Chen et al., 2005, Kim et al., 2009).  
Considering the in vitro data shown in Chapter 3.1 and published human 
genomic data, the Spry2 and Pten heterozygous mouse model was generated to 
investigate the effect of SPRY2 and PTEN in prostate carcinogenesis. Nkx Pten
fl/+ 
Spry2
+/- mouse were generated and the prostate tissue was harvested from mice 
around 10-12 months old. The H&E staining showed Pten
fl/+ developed PIN lesions 
in the prostate gland. The epithelial cells contained enlarged nuclei, and part of 
the epithelium showed irregular appearance and abnormal growth next to the 
normal  cells  (Figure  3.3.1).  In  contrast,  loss  of  SPRY2  and  PTEN  resulted  in 
aggressive  prostate  tumour,  the  glandular  structure  is  no  longer  visible,  and 
cancer cells infiltrated into surrounding areas (Figure 3.3.1). As expected, there 
are more Ki67 staining positive cells in the prostate epithelium of Pten
fl/+ Spry2
+/- 
mice compared to that in Pten
fl/+ mice, indicating uncontrolled proliferation in 
the  adenocarcinoma.  Evidence  suggested  that  loss  of  PTEN  leads  to  the 
activation of PI3K/AKt signalling, with both Pten
fl/+ Spry2
+/- and Pten
fl/+ showing  
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enhanced  AKT  activation,  but  the  former  with  more  aggressive  phenotype 
showed relatively higher levels of pAKT with predominantly plasma membrane 
staining.  In  addition  to  PI3K/AKT  signalling,  pERK1/2  activation  was  also 
assessed,  immunohistochemistry  (IHC)  results  suggested  enhanced  pERK1/2 
expression is restricted to only focal areas within the prostate (Figure 3.3.2). 
Altogether, concomitant loss of tumour suppressor gene Pten and Spry2 leads to 
activation of PI3K/AKT and drives aggressive prostate carcinogenesis in vivo. 
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3.4 Summary and discussion 
SPRY2 was reported to be downregulated in several cancer types including 
PC.  The  function  of  SPRY2  was  examined  using  human  prostate  cancer.  The 
results  suggested  SPRY2  acts  as  a  negative  regulator,  and  reduced  SPRY2 
expression  enhanced  cell  proliferation  and  invasiveness  in  response  to  EGF 
stimulation.  These  observations  require  the  presence  of  PTEN,  which  is 
consistent  with  Edwin’s  report  proposing  PTEN’s  essential  role  for    inhibitory 
effect  of  SPRY2  (Edwin  et  al.,  2006).  Human  phospho-kinase  array  analysis 
revealed that loss of SPRY2 activates PI3K/AKT signalling cascades, which may 
be responsible for the aggressive phenotype observed in SPRY2 KD cells. Mutual 
exclusivity test using cBio Cancer Genomic Portal showed the odd ratio was 7.58 
(p=0.002095), which is indicating a strong tendency toward co-occurrence. The 
murine model was used to examine whether PTEN and SPRY2 loss cooperate in 
prostate carcinogenesis. Nkx Pten
fl/+ Spry2
+/- mouse model indeed progressed to 
an  aggressive  PC  with  lymph  node  metastasis  by  10-12  months  of  age.  The 
prostate  tumours  exhibited  hyperactivation  of  p-AKT  rather  than  MAPK 
activation.  It  is  interesting  that  unlike  lung  cancer,  there  is  very  rare 
mutation/amplication  of  Ras/Raf  in  PC,  which  are  often  attributed  to  the 
abnormal activation of MAPK signalling. Concomitant low levels of two tumour 
suppressors  SPRY2  and  PTEN  favour  the  activation  of  PI3K/AKT  signalling 
cascades,  which  override  normal  checkpoints  to  result  in  tumour  formation. 
Collectively, these results allow us to investigate PI3K/AKT as a potential target, 
and  the  mechanism  of  SPRY2  and  PTEN  cooperation  in  RTK  needs  to  be 
elucidated. 
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4 Modulation of EGFR and ErbB2 trafficking and signalling 
following SPRY2 KD  
Prostate organogenesis and tumorigenesis are both critically dependent on 
androgen  receptor  (AR)  signalling  (Potente  et  al.,  2007).  Androgen  depletion 
therapy  is  often  used  but  will  eventually  result  in  progression  to  castrate 
resistant  disease.  Recent  studies  proposed  that  abnormal  activity  of  receptor 
tyrosine kinases (RTK), particularly deregulated EGFR signalling is attributed to 
the acquisition of an androgen independent state in prostate cancer (Traish and 
Morgentaler, 2009). Despite an important role for the EGFR system, targeted 
therapies against the EGFR system in prostate cancer have been disappointing 
(Trotman  et  al.,  2003a).  Such  discrepancies  may  be  explained  by  complex 
regulatory  mechanisms  for  the  EGFR  system  and  its  downstream  signalling 
cascade. 
EGFR is a member of the ErbB family, which also consists of HER-2, 3 and 
4.  Epidermal  growth  factor  (EGF)  binding  at  cell  surface  induces  receptor 
dimerization,  activation  of  its  tyrosine  kinase  domain  and  subsequent 
downstream  signalling  events,  including  both  phosphatidylinositol  3-kinase 
(PI3K)/AKT  and  Ras/Raf/MEK  pathways,  which  are  pivotal  in  controlling 
proliferation  and  survival  (Baluk  et  al.,  2007,  Dejana  et  al.,  2007a). 
Concurrently, upon EGF binding, the receptor-ligand complexes internalise into 
endosomal  compartments.  Previously,  the  primary  role  of  endocytosis  was 
thought to terminate activation of RTKs. The attenuation of the receptors by 
endosomal  degradation  was  even  proposed  to  have  a  tumour  suppressor  role 
(Zhang et al., 1997, Kim et al., 2002a). However, several studies revealed that 
RTKs  continuously  recruit  signalling  molecules  at  the  intracellular 
compartments,  maintaining  and  amplifying  its  signalling  outcome.  EGFR 
signalling  forms  a  complex  signalling  network  with  positive  and  negative 
regulators.  SPRY  protein  was  first  described  by  Hacohen  and  colleagues 
(Hacohen  et  al.,  1998),  as  an  antagonist  of  fibroblast  growth  factor  (FGF) 
signalling in Drosophila. Sprouty (SPRY) proteins are commonly deregulated in 
human  cancers  including  melanoma  and  colon  cancer  (Weber  et  al.,  2007, 
Woodfin et al., 2007). More recently, clathrin-mediated endocytosis upon EGFR  
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activation appeared to be particularly important for the activation of AKT and 
MAPK (Kim  et  al.,  2002b). Zwang and Yarden (Zwang and Yarden, 2006) also 
proposed that the fate of EGFR was determined by the status of the stress kinase 
p38  MAPK,  the  activation  of  which  allowed  tumour  cells  to  evade 
chemotherapeutic agents.  
4.1 Loss of SPRY2 alters EGFR localisation and internalisation  
Upon ligand binding, EGFR is involved in a series of trafficking events, 
which ultimately regulate its signal amplification and propagation. To determine 
how SPRY2 KD promotes EGF driven growth and invasion described in Chapter 3, 
we  investigated  the  intracellular  distribution  of  EGFR  using  fluorescence 
microscopy.  Both  Nsi  control  and  SPRY2  KD  DU145  cells  were  transiently 
transfected  with  GFP-tagged  EEA1  plasmid  transiently,  which  labels  the 
endosomal  compartment  within  the  cells.  In  unstimulated  cells,  EGFR  was 
predominantly  localised  to  the  cell  surface.  Following  EGF  stimulation,  EGFR 
began to co-localise with EEA1 positive early endosomes in both Nsi control and 
SPRY2  KD  cells  at  20  and  30  minutes.  Importantly,  at  30  minutes  following 
stimulation  with  EGF,  SPRY2  KD  DU145  cells  showed  enhanced  and  sustained 
localisation of EGFR at the early endosomes compared to the Nsi control cells 
(Figure 4.1.1). 
To  characterise  the  molecular  basis  of  EGFR  trafficking  to  the  early 
endosomes, the internalisation kinetics of EGFR in SPRY2 KD DU145 cells was 
studied.  Cell  surface  proteins  were  labelled  with  NHS-S-S-biotin,  and  then 
stimulation  with  EGF  allows  various  surface  protein  to  endocytose  including 
EGFR at the indicated time. In order to capture internalised and biotin labelled 
EGFR, surface biotin was reduced with cell impermeable reducing agent. IP was 
carried out with EGFR antibody linked dynabeads after reducing surface biotin. 
This allowed us to pull down EGFR labelled with biotin at surface and trafficked 
into the endosomal compartments. As a control, surface biotin was not removed 
from the sample at 0 minutes. For subsequent time points only biotin-labelled 
EGFR  (internalised  EGFR)  were  detected  with  HRP-avidin  among  pulled  down 
mixture  of  labelled  and  unlabelled  EGFR  pool.  Western  blot  analysis  showed 
similar total EGFR level in Nsi and SPRY2 KD cells. However, increased level of  
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intracellular EGFR in SPRY2 KD DU145 cells following EGF treatment for 15, 30 
and 60 minutes in the presence of primaquine (a receptor recycling inhibitor). 
Increased internalisation and accumulation of EGFR in SPRY2 KD cells was also 
studied using the NHS-S-S-biotin internalisation assay in an ELISA format. 96-well 
plates were coated with EGFR antibody and incubated with whole cell lysates, 
which were collected after internalisation assay. There was significantly more 
(20%) intracellular EGFR detected in SPRY2 KD cells compared with Nsi control 
cells at 30 minutes of EGF stimulation (Figure 4.1.2).  
EGFR trafficking employs mainly clathrin-dependent endocytic machinery, 
which  recruits  receptor  clusters  into  clathrin-coated  pits  and  the  membrane 
invaginations  followed  by  vesicle  scission  forming  cargo-containing  receptors. 
GTPase  dynamins  are  involved  in  constriction  and  fissions  of  vesicle  stalks, 
cooperating with Rab family proteins (Mosesson et al., 2008, Zerial and McBride, 
2001). In order to assess if the discrepancy in AKT hyperactivation is due to EGFR 
trafficking, we used dynasore, a cell permeable inhibitor of dynamin to inhibit 
clathrin-mediated endocytosis. Indeed, dynasore inhibited EGFR endocytosis in 
both control and SPRY2 KD cells. Significantly, EGF induced activation of p-AKT 
in SPRY2 KD cells was abolished, confirming the importance of endosomal EGFR 
in  promoting  PI3K/AKT  signalling  (Figure  4.1.3).  Altogether,  loss  of  SPRY2 
promotes rapid internalisation and sustained accumulation of intracellular EGFR 
in response to EGF stimulation to enhance AKT activation in SPRY2 KD cells. 
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4.2  SPRY2  KD  increases  EGFR  endocytosis  via  p38  in  a  PI3K 
dependent manner 
P38 is a key regulator of EGFR and implicated in phosphorylation of EGFR 
at  Ser-1046/1047,  which  is  closely  linked  to  internalisation  of  the  receptor 
(Nishimura et al., 2009). Furthermore, Zwang and Yarden proposed that chronic 
activation  of  p38  facilitates  accumulation  of  EGFR  in  the  endosomal 
compartments and aids tumour cell survival (Zwang and Yarden, 2006). We also 
observed  an  elevated  phospho-p38  level  in  SPRY2  KD  cells  in  the  Human 
Phospho-kinase array in Figure 3.2.1.  This was further confirmed by the Western 
blot analysis in SPRY2 KD DU145 cells. Phosphorylation of EGFR and p38 were 
increased at both 15 and 30 minutes following stimulation with EGF in SPRY2 KD 
cells  (Figure  4.2.1).  In  order  to  examine  the  role  of  p38  in  terms  of  EGFR 
signalling and its downstream signalling in SPRY2 KD cells, cells were treated 
with  p38  inhibitor  SB203580,  which  is  a  pyridinyl  imidazole  derivative.  The 
fluorine  in  the  SB203580  compound  interacts  with  ATP  binding  pocket  in  p38 
MAPK, which inhibits AKT binding (Gum et al., 1998).  
First of all, the inhibitory efficacy of SB203580 was examined, Western 
blot showed a decrease in phosphorylation of ATF2 in both control Nsi and SPRY2 
KD cells in the presence of the inhibitor. Transcription factor ATF2 is a direct 
downstream target of p38. Next, we observed a reduction in phosphorylation 
levels of EGFR and AKT when treated with the inhibitor in both Nsi and SPRY2 KD 
cells (Figure 4.2.2). Treatment with SB203580 decreased cell growth by over 30% 
(from 40% to <10%, or 4 fold reduction), compared with vehicle control sample in 
SPRY2 KD cells. The Nsi control cells also showed a reduction in proliferation 
with  a  fall  of  just  over  10%  (or  2  fold)  in  growth  rate  following  inhibitor 
treatment  (Figure  4.2.3).  Furthermore,  cells  were  also  transfected  with  p38 
siRNA and Western blot analysis showed lower p38 expression level in both Nsi 
and SPRY2 KD cells compared to the negative control lanes. The growth rates 
were  reduced  to  similar  level  seen  with  the  p38  inhibitor  treatment  samples 
(Figure 4.2.4). 
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In order to examine the effect of SB203580 in EGFR internalisation, cells 
were  pre-treated  with  p38  inhibitor  and  internalisation  assay  was  performed 
using ELISA assay. The effect of inhibition on EGFR internalisation was observed 
from 15 minutes in SPRY2 KD cells, but EGFR internalisation was not affected in 
Nsi control cells at both time points (Figure 4.2.5). It is reasonable that as there 
was not much active p-p38 detected in the western blot analysis, we may expect 
that  p38  inhibition  would  not  affect  the  amount  of  internalised  EGFR  in  Nsi 
control  cells.  However,  at  30  minutes  EGF  treatment,  there  were  a  20% 
reduction of EGFR internalised in SB203580 treated SPRY2 KD cells compared to 
the vehicle treated cells. In addition, the localisation of EGFR was visualised in 
cells treated with the p38 inhibitor using confocal microscopy. We transfected 
cells with EEA1-GFP plasmid to label early endosomes, and cells were treated 
with vehicle or p38 inhibitors prior to IF analysis. Similarly, there was a notable 
reduction in endosomal EGFR in inhibitor treated SPRY2 KD cells compared to 
vehicle  treated  cells  (Figure  4.2.6).  These  results  indicated  that  cooperation 
between activated p38 MAPK and loss of SPRY2 in EGFR signalling cascades play 
a  critical  role  in  the  trafficking  of  the  receptor  and  consequently  led  to 
uncontrolled PI3K/AKT activation. To understand the crosstalk between PI3K and 
p38  MAPK,  we  used  PI3K/AKT  inhibitor,  LY294002,  to  examine  the 
phosphorylation of EGFR and p38. The PI3K inhibitor abolished both EGFR and 
p38 phosphorylation in Nsi and SPRY2 KD cells (Figure 4.2.7). Furthermore, loss 
of  SPRY2  in  PTEN  null  PC3  cells  results  in  rapid  degradation  of  EGFR  and 
subsequently no difference in PI3K/AKT activation observed between SPRY2 KD 
and Nsi control cells (Figure 4.2.8). We concluded that upon ligand binding to 
EGFR, this leads to enhanced activation of PI3K/AKT in SPRY2 KD cells, which in 
turn phosphorylates p38 MAPK. Consequently EGFR phosphorylated at serine and 
threonine sites enhances internalisation and continuous signalling in a positive 
feedback loop in a PTEN dependent manner.   
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4.3 EGFR cooperates HER2 trafficking but not HER3 
Abnormal EGFR trafficking and its downstream signalling in SPRY2 KD cells 
indicated the potential use of EGFR tyrosine kinase inhibitors, such as gefitinib 
(also known as Iressa). Surprisingly, SPRY2 KD cells showed significant survival 
advantage  over  Nsi  control  cells  upon  treatment  with  gefitinib.  Hetero-dimer 
formed by EGFR and other HER family members including HER2 and HER3 may 
confer  a  selective  growth  advantage  and  can  lead  to  resistance  to  selective 
tyrosine kinase inhibitor such as gefitinib (Tomlins et al., 2005). We investigated 
the involvement of HER2 in EGF stimulated cells. Interestingly, SPRY2 KD cells 
respond  to  EGF  treatment  with  enhanced  and  sustained  phospho-HER2  levels 
(Figure 4.3.1).  Hence, lapatinib, a dual inhibitor of both EGFR and HER2, was 
examined to assess the ability to inhibit SPRY2 KD cell growth more efficiently 
than gefitinib. Indeed the anti-mitotic effects of lapatinib were very comparable 
in both control and SPRY2 KD cells. There is over 30% reduction compared to 
vehicle  treated  cells,  and  more  than  25%  reduction  of  cell  proliferation  was 
observed compared to gefitinib treated cells. Furthermore, heregulin activated 
both HER3 and HER2 in DU145 cells, but only HER2 activation and cooperation 
were observed in the presence of EGF not HER3. There were similar levels of 
AKT  phosphorylation  in  both  Nsi  and  SPRY2  KD  cells  when  stimulated  with 
heregulin. Whereas EGF stimulates more AKT in SPRY2 KD cells, which may be 
attributed  to  the  trafficking  mediated  by  EGFR  and  HER2  activation  (Figure 
4.3.2). This suggests in spite of functional HER3 in DU145 cells, only EGFR and 
HER2 heterodimers contributed to the enhanced cell growth in the presence of 
EGF in SPRY2 KD cells.  
There are multiple pieces of evidence to suggest a critical role for EGFR 
and  HER2  in  PC  cell  proliferation  and  invasion,  especially  castration-resistant 
disease  (Zhan  et  al.,  2006,  Mellinghoff  et  al.,  2004).  In  order  to  assess  the 
kinetics of HER2 trafficking in EGF stimulated cells, the internalisation assay and 
Neutravidin immunoprecipitation (IP) were performed to pull down internalised 
proteins with NHS-S-S-biotin label. The biotinylated proteins were pulled down 
with NeutrAvidin agarose. The neutravidin beads IP internalised proteins, which 
were labelled at the cell surface with biotin in the beginning of the experiment. 
The  IP  results  show  clear  increase  of  HER2  accumulation  in  SPRY2  KD  cells  
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following  EGF  treatment  at  60  minutes.    Whereas,  there  were  surface  HER3 
labelled with the biotin, but no endosomal HER3 detected in Nsi and SPRY2 KD 
cells (Figure 4.3.3). This supports the observation that HER3 was not significantly 
activated upon EGF stimulation. 
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SPRY2 expression was characterised in two independent PC cohorts in the 
format of tissue microarray (TMA).  The TMA included 202 cases of PC and 107 
cases of benign prostatic hyperplasia (BPH) as controls. Patients with reduced 
SPRY2  expression  were  stratified  according  to  the  HER  paralogue  expression 
status:  those  patients  with  HER2  positive  disease  have  significantly  poorer 
survival outcomes compared with those with HER2 negative disease (Log rank: 
p=0.014)  (Figure  4.3.4).  The  IHC  staining  of  human  prostate  tissue  showed 
membrane and cytoplasmic HER2 immunoreactivity. None of the other members 
of  the  ErbB  receptors  including  HER3  and  HER4  showed  any  association  with 
patient outcome. Since the interaction between RTK trafficking and SPRY2 loss 
occurs  in  a  PTEN  dependent  manner,  we  segregated  TMA  into  two  groups, 
moderate  and  low  PTEN  expression.  Moderate  indicates  PTEN  expression  was 
below  median  of  BPH  but  above  median  of  the  cancer  population.  Low 
expression  was  relatively  less  PTEN  expression  than  median  score  in  cancer 
samples, which meant it included a histoscore of zero. The correlation analysis 
indicated a significant positive association between cytoplasmic HER2 and p-AKT 
among patients with moderate PTEN expression level, but p-ERK1/2 correlation 
is  not  significant  (n=110),  emphasising  the  importance  of  p-AKT  in  prostate 
carcinogenesis.  Moreover,  SPRY2  negatively  correlated  with  both  cytoplasmic 
and membrane HER2 and p-AKT, the association between SPRY2 and p-ERK1/2 
was not significant. Interestingly, the association between SPRY2 and p-AKT was 
lost in the low PTEN expressing PC (p=0.589, n=110) (Table 4.1). These TMA data 
suggests the in vitro hypothesis that loss of SPRY2 leads to hyperactivation of 
PI3K/AKT  via  RTK  trafficking  in  a  PTEN  dependent  manner  and  promotes  PC 
development.  
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4.4 Summary and discussion 
The binding of ligands to EGFR leads to homo- and hetero-dimerization 
with members of the HER kinase family (Voeller et al., 1997). Interestingly, we 
observed  the  involvement  of  HER2,  but  not  HER3,  in  the  flow  of  EGFR 
trafficking;  further  contributing  to  enhanced  RTK  mediated  intracellular 
signalling.  P38-mediated  phosphorylation  of  EGFR  can  then  evade  receptor 
degradation  to  produce  sustained  and  enhanced  signalling  at  the  endosomes. 
Consistent with our findings, Zwang and Yarden (Zwang and Yarden, 2006) also 
postulated that chronic stress induced p38 activation either intrinsically in in 
vivo growth or associated with treatment such as cytotoxic dugs can enhance 
EGFR localisation to the endosomes with a pro-survival effect. In our PC TMA 
cohorts, reduced SPRY2 and upregulated p-AKT was significantly associated, but 
not with ERK activation, suggesting specific oncogenic choice for the cancer with 
SPRY2 loss. Interestingly, the PTEN status is crucial for such association, since 
among  the  PTEN  negative  tumours  (histoscore  zero)  showed  no  correlation 
between low SPRY2 and activation of AKT.  In conclusion, complex interactions 
among  RTKs  and  their  downstream  effectors  exhibit  fine  regulation  of  the 
signalling networks to involve distinct signalling molecules, which may represent 
important  targets  for  developing  treatment  in  the  context  of  personalised 
medicine.  
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Chapter 5. Low SPRY2 and PTEN as biomarkers for 
PC responsive to PI3K inhibitor therapy  
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5 Low SPRY2 and PTEN as biomarkers for PC responsive to 
PI3K inhibitor therapy 
Accumulating  genetic  evidence  and  cancer  research  suggest  that  the 
PI3K/AKT  signalling  cascade  is  pivotal  in  cancer  initiation  and  growth.  In 
prostate cancer, the main reason for abnormal activation of PI3K/AKT activation 
is  related  to  the  loss  of  PTEN  including  haplosufficiency  and  biallelic  loss. 
Activation  of  RTKs  also  accounts  for  another  important  mechanism  for  the 
activation of PI3K/AKT in cancer. Briefly, activation of the PI3K/AKT signalling 
pathway  often  results  from  RTK  (Roche  et  al.,  1998).  PI3K  is  a  heterodimer 
consisting  the  p85  regulatory  subunit  and  the  p110  catalytic  subunit.  The 
regulatory domain directs the translocation of PI3K to the plasma membrane, 
while  the  catalytic  domain  phosphorylates  PIP2  (phosphatidylinositol-4,5-
bisphospate)  at  the  plasma  membrane,  which  is  part  of  the  membrane 
compartment,  to  generate  the  second  messenger  molecular  PIP3 
(phosphatidylinositol-3,4,5-trisphospate).  The  production  of  PIP3  leads  to  the 
activation of PI3K and downstream signalling including PDK1 (phosphoinositide-
dependent  protein  kinase1)  and  AKT  through  physical  interaction  (Engelman, 
2009).  Several  small  molecules  are  developed  to  inhibit  PI3K/AKT  signalling 
including  dual  PI3K/mTOR  inhibitor,  PI3K  inhibitor,  AKT  inhibitors  and  mTOR 
inhibitors.  Unlike  breast  and  lung  cancer,  the  amplification  of  HER2  and 
mutation  of  EGFR  are  rare  in  prostate  tumours.  Yet,  the  tight  spatial  and 
temporal regulators of RTKs including SPRY2 are often deregulated in prostate 
cancer.  Loss  of  SPRY2  in  DU145  cells  showed  hyperactivation  of  PI3K/AKT  in 
response  to  EGF  stimulation.  In  addition,  reduction  of  SPRY2  expression  in 
prostate cancer cells exhibited rapid EGFR trafficking along with HER2, which 
led to the enhanced downstream signalling cascades including PI3K/AKT. In this 
study, the effect of a dual inhibitor PI103 was investigated in Nkx CRE Spry2
+/- 
Pten
fl/+ mouse model described in Chapter 3. 
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5.1  PI3K  inhibitor  reduced  SPRY2  KD  cell  lines  growth  and 
invasiveness 
As PI3K plays an important role in cancer biology, much interest has been 
generated  to  develop  inhibitors  as  potential  therapeutic  agents.  The 
understanding  of  the  PI3K  crystal  structure  has  led  to  the  design  of  small 
molecules including well-known compounds LY294002 and wortmannin. LY294002 
has  been  shown  to  inhibit  PI3K  more  selectively  than  other  protein  kinases 
including EGFR and protein kinase C (Vlahos et al., 1994). In spite of antitumour 
effects of LY294002 in in-vitro and in-vivo models, its toxic side effects and poor 
solubility prevented the compound from entering clinical trials. As a laboratory 
cell based reagent, LY294002 is a useful tool to understand the function of PI3K 
in tumorigenesis. Furthermore, MAPK inhibitor PD098059 is also used to study 
the function of ERK1/2 in SPRY2 KD cells. The compound can inhibit MEK1 direct 
upstream of ERK1/2. 
Our  working  model  is  that  loss  of  SPRY2  interacts  with  abnormal  RTK 
signalling to drive PI3K/AKT hyper-activation mediated prostate carcinogenesis. 
Therefore, to test the significance of PI3K/AKT signalling, SPRY2 KD DU145 cells 
were treated with the PI3K inhibitor LY294002 and studied in proliferation and 
invasion  assays.  SPRY2  KD  DU145  showed  significantly  reduced  growth  and 
invasion in the presence of LY294002. In contrast, the MAPK inhibitor PD098059 
did not have any effects (Figure 5.1.1).   
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5.2  SPRY2  and  PTEN  mouse  model  to  identify  PI3K  inhibitor 
responsive prostate tumours 
In the Nkx CRE Spry2
+/- Pten
fl/+ mouse prostate model, high level of p-
AKT, but not phospho-ERK1/2, staining was evident in the prostate of 3 months 
old  animals  (Figure  5.2.1).    Hence,  the  in  vivo  significance  of  SPRY2  loss 
associated AKT activation was examined using the potent PI3K inhibitor PI103. 
The compound is a selective class I PI3K inhibitor (IC50=3 nmol/L) and is around 
200 fold more potent than LY294002 (IC50= 600 nmol/L). PI103 was also tested 
for the effect on other tyrosine kinases, a screen against over 70 protein kinases 
showed little or no inhibitory activity. In vitro studies with human cancer cell 
lines showed inhibitory effects on proliferation of prostate, lung, ovarian and 
colon cancer cell lines (Carracedo et al., 2011b).  
In Nkx CRE Spry2
+/- Pten
fl/+ mice the prostate tumour was palpated in the 
mouse  model  (10-11  months).  PI  103  was  injected  daily  50  mg/kg  intra-
peritioneal  (ip)  for  4  weeks,  when  tumours  were  apparent.  The  prostatic 
epithelium showed significantly fewer Ki67 positive cells (Figure 5.2.2), which is 
indicative of reduced proliferation. When compared to vehicle control treated 
mice, using a combination of western blotting and immunohistochemistry (IHC) 
experiments, p-AKT level was significantly reduced following PI3K inhibition. The 
H&E  staining  confirmed  the  presence  of  aggressive  tumours  in  the  vehicle 
treated mice (10-12 months). In contrast, PI103 treated animals, the prostate 
was  filled  with  lymphocytic  infiltration  and  the  epithelial  cells  retained 
differentiated structure with a glandular architecture (Figure 5.2.3). It is worth 
noting that, even in the presence of increasing tumour bulk and invasion, these 
tumours retained their PTEN expression as shown by western blot analysis and 
IHC staining. PTEN immunoreactivity was observed at high level in lymphocytes 
(Ly) and at relatively lower level in the epithelial (Ep) cells (Figure 5.2.4), thus 
excluding  the  involvement  of  de  novo  loss  of  the  remaining  PTEN  allele. 
Prostatic lesions in these animals following PI 103 treatment were noticeably 
cystic (Figure 5.2.3) when compared to the solid nature of tumours in control 
treated animals (n=6). Hence, the lymph node status was used as an endpoint to  
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test  the  potential  role  of  PI3K  signalling  in  PC  progression.  In  the  cohort  of 
Spry2
+/-  Pten
fl/+  mice  studied,  3  of  4  animals  treated  with  vehicle  control 
developed metastatic lymph node lesions with evidence of androgen receptor 
expression.  However,  none  of  the  four  PI  103  treated  animals  developed 
metastatic  nodal  disease  (p=0.025  Figure  5.2.5).  Furthermore  there  was  no 
change  observed  in  phospho-ERK1/2  level  in  prostates  of  both  treated  and 
untreated animals (Figure 5.2.4). Enhanced apoptosis as illustrated by pyknotic 
and roughly rounded nuclei on TUNEL assay was also observed in PI 103 treated 
tumours  (Figure  5.2.6).  Furthermore,  EGFR  staining  showed  cytoplasmic  and 
plasma membrane localisation in the vehicle treated prostate tissue, whereas 
the PI3K inhibitor treated tissue showed very little or no immunoreactivity of 
EGFR (Figure 5.2.7). In summary, the potent PI3K inhibitor significantly reduced 
tumour  burden  in  Spry2
+/-  Pten
fl/+  mice,  which  suggested  enhanced  PI3K/AKT 
signalling plays a key role in PC driven by SPRY2 and PTEN loss.  
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5.3 Summary and discussion 
Recent evidence suggested combinatory targeted therapies could be more 
effective.  For  instance,  MAPK  and  PI3K/AKT  are  simultaneously  and 
synergistically activated in a PTEN
+/- mouse prostate model (Gumerlock et al., 
1997). Our genetically modified (Nkx Cre Spry2
+/- Pten
+/-) mouse model showed 
evidence of PI3K/AKT hyper-activation, without MAPK activation, in the prostate 
and  enhanced  capability  to  develop  metastatic  nodal  disease  by  12  months. 
Significantly, the PI3K inhibitor PI103 exerted a dramatic inhibitory effect on the 
growth of nodal metastasis. In addition, the reduction of SPRY2 expression has 
been associated with high-grade prostate tumour, and patients often are treated 
with androgen depletion therapy. Combination of PI3K and androgen inhibition 
strategies  may  delay  the  onset  of  androgen  independent  disease  progression. 
Hsieh and his colleagues suggested the importance of 4EBP-elF4E in translational 
components  and  as  a  potential  target  in  AKT-mediated  lymphoma  and 
rapamycin-resistant  tumours  (Hsieh  et  al.,  2010).  Indeed,  as  PI3K/AKT  are 
important upstream kinases, there are many downstream targets that may need 
further assessment for potential therapeutic strategies. 
Taken  together,  the  selective  activation  of  PI3K/AKT  associated  with 
SPRY2  loss  in  the  context  of  PTEN  insufficiency  is  important  in  prostate 
carcinogenesis:  PI3K/AKT  function  enhances  EGFR/HER2  signalling;  PI3K/AKT 
promotes  a  proliferative  and  an  invasive  phenotype  in  vitro  and  in  vivo; 
suppression  of  PI3K/AKT  function  reverse  the  above  in  vitro  and  in  vivo 
phenotype;  and  finally,  upregulated  p-AKT  expression  was  closely  associated 
with reduced SPRY2 expression in clinical PC.  
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6 SILAC analysis of SPRY2 interacting partners 
In the last few decades, there has been an explosion of information and 
understanding in human genetics, which has given biologist a great insight into 
what  we  are  made  of  and  particularly  be  able  to  pinpoint  many  forms  of 
diseases. No doubt, the genetic information reveals generally mutations, copy 
number changes and level of mRNA particularly in tumour biology, which has 
greatly improved prognosis and therapy. There are significant gap in our ability 
to translate tumour biology information into clinical application aimed for better 
patient  proteome.  The  majority  of  enzymatic  reactions  are  carried  out  by 
various  proteins  in  the  cell,  and  proteins  undergo  many  post-translational 
modifications,  compartmental  trafficking,  physical  interaction  with  other 
partners and degradation. These processes are tightly controlled via many forms 
of  feedback  and  signalling  networks.  Recently,  many  novel  technologies  have 
been developed to study the behaviour of proteins in a high throughput manner, 
namely proteomics. In tumour biology, complementary to genomic knowledge 
the global profiling of the protein pattern can be studied to compare normal and 
diseased conditions, in the hope of identifying molecular markers in order to 
elucidate  disease  mechanisms,  including  the  initiation  and  progression  of  the 
disease. 
At present there are two types of labelling protocols commonly used in 
mass  spectrometry  (MS),  including  biological  and  chemical  incorporation.  The 
biological  labelling  of  the  proteins  in  the  cell  is  achieved  by  adding  stable 
isotope-containing anabolites to the media for cells to grow in tissue culture and 
this approach is used in this project. The purpose of using stable isotopes (
13C, 
15N, 
2H) is that the MS quantitative analysis of protein/peptides can distinguish 
between test samples by comparison of distinct molecular mass peaks of the 
labelled  proteins,  which  gives  a  relative  ratio  of  abundance  of  the  different 
labelled isotopic forms present in the various test samples.  
Typical SILAC MS is achieved by culturing two /three groups of cells in 
culture  media  containing  ‘light’,  ‘medium’,  and  ‘heavy’  labelled  amino  acids 
(aa) (often with lysine and arginine). Since these aa are not synthesised by the 
cells, the labelled aa are incorporated into the cell in approximately 5 doubling  
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time.  The  SILAC  method  is  a  straightforward  and  efficient  comparison  of 
chemical incorporation, because there is no need to remove additional labels 
from the media or involve multiple steps for the labelling. In terms of signal-to-
noise  quantitative  analysis  still  require  further  development  in  future  MS 
instrument and methodology. The samples in this project are prepared using the 
whole cell lysates, which means the quantification of the protein change may 
not capture the accurate interactions due to the disruption and dilution of the 
native conditions, particularly for those interactions, which occur in different 
intracellular compartments. To date there are different methods in quantitative 
proteomics, which have their advantage and limitations. Inevitably the global MS 
analysis  will  provide  an  enormous  volume  of  quantitative  data,  although  the 
ability to filter out specific/useful information would be the challenge in the 
future when the MS becomes a routine technique. 
In this project, GFP-tagged SPRY2 is transiently overexpressed in prostate 
cancer  cell  lines,  and  SPRY2  interaction  proteome  studied  following  EGF 
stimulation,  which  may  give  an  insight  into  the  mechanisms  of  SPRY2 
involvement in RTK signalling and trafficking. Potential interaction partners of 
SPRY2 may give better understanding of how SPRY2 exerts its inhibitory action, 
and consequently may help us to identify potential targets involving SPRY2 loss 
in carcinogenesis. Particularly in the presence of EGF, we have shown that loss 
of SPRY2 enhances prostate cancer development through EGFR/HER2 activation. 
An overview of the experimental design is shown in Figure 6.1.1. 
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6.1 Generation of SPRY2 overexpression model 
In  order  to  further  understand  the  action  of  SPRY2  in  prostate 
carcinogenesis, endogenous SPRY2 IP was performed in DU145 cells. Firstly, the 
SPRY2 antibody was crosslinked to agarose beads and titration experiment was 
carried out with increasing volume of agarose beads. Western blot analysis with 
post IP supernatants (S) and IP sample indicated that 3 µl of beads volume is the 
optimal condition (Figure 6.1.2). Up to 1 µl beads volume, the level of SPRY2 in 
supernatants  was  still  higher  than  in  the  post  IP  supernatants  following 
incubation  with  3-10  µl  beads,  although  the  non-specific  signals  were  also 
weaker.  Hence, 3 µl beads per 2 mg of proteins were chosen for the future IP.  
For MS analysis, 10
6 cells were seeded and lysed on a 15 cm diameter dish 
and the protein concentration was determined using BioRad and Bradford assay. 
Samples were run on a 10% SDS-PAGE gel (Invitrogen), and the protein bands 
were visualised with Simply Blue
TM SafeStain (coomassie blue staining kit) (Figure 
6.1.3). Even with optimised beads volume, there are many non-specific bands in 
beads alone lane, which was IP with beads without primary antibody crosslink. 
The SPRY2 protein bands were expected to be the most prominent in the IP lane, 
but  this  was  not  observed.  Nonetheless,  there  was  a  double  band  at  43  kDa 
marker, which was identified as SPRY2 with MS. However the list of proteins 
pulled down were mostly nonspecific or mostly bead specific namely beadome 
including actin and actin related proteins. 
It is reasoned that the amount of SPRY2 in DU145 are limited and the 
primary antibody may not be as specific as we wished for IP. Next, the flag-
tagged SPRY2 plasmid was used to transiently transfect prostate cancer cell lines 
to  increase  the  amount  of  SPRY2  expression  level,  and  to  overcome  the 
difficulties. The efficiency of the plasmid transfection was assessed using IF, the 
endogenous SPRY2 showed punctuated staining near perinuclear localisation. In 
contrast, the flag-tagged SPRY2 localised all over the cytoplasm of the cell, with 
no specific localisation (Figure 6.1.4). In addition, SPRY2 antibody was not able 
to recognise the Flag-tagged SPRY2, since the endogenous SPRY2 signal was not 
overlapping with Flag signal. It may be due to the fact that Flag was tagged on 
the N-terminus of SPRY2 protein, where SPRY2 antibody recognises the protein.  
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The  Flag  IP  was  performed  with  caution,  since  SPRY2  expression  seems 
overwhelming. As expected, the MS identified many Flag-bead specific proteins, 
with the most abundant protein identified to be SPRY2. In order to overcome 
such  problem,  GFP  tagged  SPRY2  plasmid  was  generated  by  inserting  SPRY2 
sequence  into  pEGFP-C1  plasmid  (Figure  6.1.5).  Cells  were  transfected  with 
pEGFP-C1 as control or GFP-SPRY2 plasmid, and visualised under the microscope. 
Interestingly,  SPRY2-GFP  localised  to  the  peri-nuclear  region,  similar  to 
endogenous SPRY2 (Figure 6.1.6). The transfection rate was only between 20-
30%, and the transfection reagent lipofectamine 2000 was toxic. Prior to the MS 
quantification, the samples were analysed by western blot. GFP and GFP-tagged 
SPRY2  were  detected  in  whole  cell  lysates  (WCL)  samples  lane  1  and  2 
respectively in Figure 6.1.7. The efficiency of GFP pull down was tested with 
post IP WCL, which was collected after separation of beads from the lysates. As 
expected, the GFP-SPRY2 transfected sample (2) had reduced amount of SPRY2 
compared to the initial WCL. In the IP sample, the empty vector and GFP-SPRY2 
lanes  were  confirmed  to  have  high  levels  of  GFP  and  GFP  tagged  SPRY2 
respectively.  The  endogenous  SPRY2  was  detected  in  all  lanes  except  in  the 
negative control IP sample. Furthermore, a positive interaction partner of SPRY2 
was assessed. It is reported that both SPRY2 and SPRY4 directly binds to wild 
type  BRAF  (not  V599E  mutant)  and  interferes  with  MAPK  signalling  cascades 
(Lampugnani and Dejana, 2007). BRAF was detected across all of the cell lysates 
with  weak  signal,  and  the  GFP-SPRY2  IP  sample  showed  the  strongest  band, 
indicating  the  interaction  between  exogenous  GFP-SPRY2  and  BRAF.  These 
results suggested that GFP-tagged SPRY2 transfection system could be used for 
SILAC MS/MS analysis. 
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6.2 Analysis of SILAC mass spectrometry 
Firstly, PC3 cells were passaged in culture media containing isotope labels 
shown in Table 2.3. After 5 passages, the whole cell lysates were collected and 
the incorporation of the isotopes assessed. Such growth media did not show any 
detrimental effect on cell growth and morphology. The samples were prepared 
as illustrated in Figure 6.1.1, the protein sequences of the GFP-tagged SPRY2 is 
shown below (Figure 6.2.1). For the negative control, the empty vector pEGFP-
C1 was transfected. Both samples were run on a SDS-PAGE gel and stained with 
coomassie blue. As expected, GFP-SPRY2 (61 kDa) was the most prominent band 
was between 72 and 55 kDa. The negative control lane had a strong band around 
34 kDa marker, which was the GFP tag alone (Figure 6.2.2). The gel was cut as 
indicated,  digested  with  trypin,  and  performed  LC  MS/MS  analysis.  The  MS 
analysis  identified  around  90  different  proteins.  GFP  beadome,  and  proteins 
identified in the negative control samples were excluded from the candidate 
lists. For example, variants of heat shock 70KDa protein, cytokeratin 8 and 18, 
and ubiquitin are most commonly detected in GFP pull down (Trinkle-Mulcahy et 
al., 2008). Indeed these proteins were identified in both empty vector and GFP-
SPRY2 IP samples. In addition, there are also sepharose bead associated non-
specific binders, including cofilin, filamin, vimentin, plectin, actin, myosin, and 
tubulin, which are cytoskeletal, motility or structural protein families. Also, it is 
reported that various histones, heat shock proteins, ribosomal proteins, hnRNP 
proteins and translational factors are mostly pulled down with sepharose beads 
IP.  Considering  the  non-specific  binding  proteins,  most  of  proteins  identified 
from PC3 cell line SILAC IP were bead related protein, not SPRY2 interaction 
partners.  It  was  thought  that  in  vitro  findings  from  Chapter  3  explains  non-
inclusive results from the SILAC IP, since PTEN null PC3 cells had showed no 
effect when SPRY2 expression level was reduced. Thus, overexpression of SPRY2 
may not be functional in PTEN negative cells. 
In  contrast  to  PC3,  DU145  (PTEN  positive)  SILAC  IP  results  revealed  a 
different list of proteins as candidate interaction partners. Although GFP beads 
related non-specific binding proteins were similar as mentioned above. There 
were  interesting  potential  authentic  interacting  partners  of  SPRY2,  including 
creatin  kinase  B,  serine/threonine-protein  phosphatase  2A  (PP2A)  65  kDa  
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regulatory subunit A alpha isoform, and LIM domain only protein 7. Lao and his 
colleagues reported that SPRY2 co-IP with PP2A and regulates downstream of 
FGFR  signalling  cascade  (Lao  et  al.,  2007).  In  addition,  there  were  few 
candidates identified including creatin kinase B (CKB), LIM domain only protein 7 
(LMO7), pyruvate kinase isoenzyme M1/M2 (PKM2), and Ras GTPase-activating 
protein binding protein 1 (G3BP1) (Table 6.1).  
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6.3 Validation of its interaction partners 
In order to validate the candidates identified from the MS analysis, the 
potential  interaction  partners  were  validated  with  western  blots.  Whole  cell 
lysates were collected before and post IP, which is shown in the Figure 6.3.1. 
The  possible  candidates  suggested  by  the  SILAC  IP  were  PP2A  (protein 
phosphatase 2A), PKM2 (pyruvate kinase isoenzyme M1/M2), CKB (creatin kinase 
brain  type)  and  clathrin  heavy  chain.  There  were  difficulties  to  obtain 
commercially available antibodies, which can be used for western analysis, for 
some of candidates in the lists. PKM2, CKB and clathrin were detected in WCL 
and post IP WCL, and also in the negative control lane. The GFP beads strongly 
bind to the proteins, thus these were considered as non-specific binding, namely 
beadome. These proteins were detected in the SPRY2-GFP IP sample lane with 
weaker signal compared to negative control. Interestingly, PP2A is only detected 
in SPRY2 IP lane and WCL, but not in the negative control lane. This confirms 
that PP2A is the true binding partner of SPRY2. The peptides were identified in 
MS/MS are highlighted in the Figure 6.3.2. It has been reported that upon FGF 
stimulation SPRY2 directly binds to PP2A and the binding sites involving SPRY2 
are tyrosine 55 residue (Lao et al., 2007).  
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6.4 Summary and discussion 
Various  proteomic  techonologies  particularly  SILAC  MS  and  pre-existing 
cell biology knowledge provide many opportunities and questions to be asked in 
post genome era. The project involving endogenous SPRY2 IP demonstrated the 
difficulties underlie in cellular and technical aspects. It was due to the fact that 
the  level  of  SPRY2  expression  is  not  abundant  enough  to  pull  down  for  MS 
analysis. Kriegsheim and his colleagues (von Kriegsheim et al., 2009) managed 
for the first time to IP endogenous ERK, which is often ubiquitously expressed. 
Also commercially available antibodies for SPRY2, which is an affinity isolated 
polyclonal antibody (Sigma), may not be as specific and effective as monoclonal 
antibodies used in ERK IP.  
The separation of specific protein interactions from bead proteomes is a 
major challenge in the field. There are over 30 proteins pulled down as GFP 
specific  binding  partners  and  several  hundreds  of  proteins  interact  with 
sepharose  beads  (Trinkle-Mulcahy  et  al.,  2008).  These  proteins  are  mainly 
cytoskeletal, structural and motility proteins, which are often considered as the 
most abundant proteins in a cell. In order to increase the amount of protein 
expression,  plasmids  are  used  to  express  the  protein  of  the  interest.  As 
described  in  Chapter  6,  Flag  and  GFP  tagged  SPRY2  were  overexpressed  in 
prostate cancer cell lines. The GFP-Trap system was more effective compared to 
Flag pull down. GFP pull down validated BRaf as a positive control but not in 
Flag-tagged SPRY2 IP. In addition, the localisation of the tagged SPRY2 seemed 
more specific with GFP tag rather than Flag. Transient transfections system with 
plasmid  should  be  used  with  consideration  of  other  side  effects  including 
overwhelming the cell with the protein of interests, which is not physiological. 
Thus  the  effect  and  potential  interaction  candidates  could  well  be  non-
physiological or non-specific. Furthermore, common tags including GFP and Flag 
could affect the host protein folding, behaviour or its binding partners. 
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7 Discussion 
Recent advances in global genomic profiling have generated vast amounts 
of data from cancer patients including prostate tumour, which has provided us 
with  better  understanding  of  carcinogenesis  and  confirming  molecular 
abnormalities and revealing potential targets for therapy. Loss of PTEN plays a 
key role in PC progression, and is a hallmark of advanced disease. Indeed, cBio 
portal indicated that 16% of cases (n=194) either lost both copies or one copy of 
Pten alleles. As expected, almost half of patients have complete loss of Pten in 
patients (n=37) with advanced metastatic diseases (Taylor et al., 2010). The rest 
of metastatic disease still express PTEN, the interesting question is how these 
cancers become aggressive with PTEN retention. In this project, I examined the 
significance  of  regulatory  components  of  the  PI3K/AKT  signalling  particularly 
focused  on  SPRY2,  which  is  known  as  a  negative  regulator  of  RTK  cascades. 
Following the discovery of Drosophila SPRY as an antagonist of FGFR signalling 
pathway, many researchers have uncovered the role of mammalian SPRY family 
members  in  various  cancer  developments  (Hacohen  et  al.,  1998).  Given  the 
important  role  of  RTK  in  normal  and  tumour  development,  no  doubt  SPRY 
proteins regulate various RTK including FGFR, VEGFR and EGFR in a temporal and 
spatial manner. However, the role of SPRY members particularly SPRY2, remains 
to be elucidated in cancer biology. In advanced metastatic PC, there are a total 
of 38% of cases with downregulation of SPRY2 expression. Interestingly, half of 
the cases have PTEN complete deletion, and the other half are with retention of 
PTEN  expression  (Figure  7.1).  Considering  PTEN  is  essential  for  SPRY2’s 
regulatory role, this project focused on the role of SPRY2 in EGFR with PTEN 
expressing PC.  
Firstly, in vitro cell line studies showed that stable KD SPRY2 leads to 
enhancement in cell proliferation and invasiveness in PTEN positive DU145 cell 
lines  in  response  to  EGF  stimulation.  Engagement  of  ligands  to  EGFR  often 
results  in  MAPK  and  PI3K/AKT  signalling  activation  to  aid  cell  growth  and 
movements. Interestingly, the human phospho-kinase array suggested that the 
exacerbated  signalling  activation  in  SPRY2  KD  cells  was  associated  with  the 
hperactivation  of  PI3K/AKT.  This  project  further  investigated  the  potential 
mechanisms entailing RTK and the regulatory component of PI3K/AKT. Among  
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RTK  family,  ErbB  family  members  including  EGFR  and  HER2  involve  complex 
compartment-specific  signalling  upon  ligand  binding.  Internalisation  assay 
indicated both EGFR and HER2 (not HER3) rapidly trafficking and retention at 
endosomal compartments resulted in enhanced downstream PI3K/AKT signalling 
in SPRY2 KD cells. Such trafficking and signal amplification in SPRY2 KD cells 
required the presence of PTEN expression. Furthermore, dissection of RTK and 
PI3K/AKT  signalling  cascades  with  various  inhibitors  including  LY294002  and 
SB203580  confirmed  the  involvement  of  p38  serine/threonine  kinase  in 
protecting  RTK  from  degradation  and  facilitating  internalisation,  which  forms 
feedback  forward  loop  described  in  Chapter  4.  Thus  PC  cells  are  capable  of 
utilising  RTK  signalling  component  without  amplification  or  mutation  of  the 
receptors for cell growth unlike common amplification of HER2 in breast cancer.  
Secondly,  Nkx  Pten
fl/+  Spry2
+/-mouse  model  developed  aggressive  PC 
around  10-12  months  with  mestastatic  involvement  of  lymph  nodes.  Prostate 
tumour tissue collected from these transgenic mice showed hyperactivation of 
PI3K/AKT and enhanced cytoplasmic EGFR. This supports the hypothesis drawn 
from in vitro human cell lines. Reduction of SPRY2 expression was associated 
with  enhanced  activation  of  PI3K/AKT  signalling  cascades  in  response  to  EGF 
stimulation.  EGFR  and  HER2  heterodimers  showed  rapid  trafficking  and 
amplification of the signalling via p38 and in a PTEN dependent manner (Figure 
7.2).  In  addition,  the  mouse  model  provided  an  experimental  platform  for 
testing chemotherapy strategies. In contrast to PTEN or SPRY2, it is much easier 
to target activated PI3K/AKT signalling pathways for therapy rather than trying 
to restore the lost tumour suppressor function. One of the major challenges in 
the  clinical  use  of  PI3K  inhibitors  is  to  identify  patients  with  PC  specifically 
driven by such molecular abnormalities. However, PC is a heterogeneous disease 
with  complex  genetic  and  epigenetic  abnormalities,  which  are  difficult  to  be 
fully represented in a single transgenic mouse model. Thus this study provides an 
important insight into potential strategies for developing future combinatorial 
therapeutic approaches. Of note, both in vitro cell model and preclinical mouse 
prostate tumour responded well to the treatment with the PI3K inhibitor PI103 in 
terms of inhibition of cell proliferation and invasiveness. It is worth considering 
the  particular  patient  cohort  with  PC  showing  SPRY2  and  PTEN  along  with  
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hyperactivation  of  PI3K/AKT.  These  patients  may  be  responsive  to  targeted 
therapy to PI3K/AKT signalling. 
Thirdly,  the  human  TMA  data  further  confirms  the  important  roles  of 
PTEN, SPRY2 and RTK in PC development. Correlation analysis suggested a strong 
asscociation between SPRY2, HER2 and AKT. Loss of SPRY2 acts as a negative 
regulator  of  HER2  function  and  results  in  hyperactivation  of  AKT  in  prostate 
carcinogenesis.  Given  HER2  has  no  known  intrinsic  ability  to  bind  to  cognate 
ligands,  its  function  relies  on  the  formation  of  heterodimers  with  EGFR  and 
HER3, and the significant correlation between cytoplasmic HER2 is concomitant 
with the importance of signal amplication via internalisation of the receptors. 
For future studies, there are PC patients with both PTEN completely loss and 
downregulation of SPRY2 (10/194), which may have different profile of abnormal 
molecular mechanisms contributing PC progression. Further research of in vivo 
models with homozygous deletion of Spry2 and Pten may give insight into other 
potential therapeutic targets for this particular subset of patient. 
Finally, cancer is generally believed to be a multistep genetic disorder 
(Potente  et  al.,  2007).  Either  by  loss  of  tumour  suppressor  gene  or 
hyperactivation  of  specific  oncogene,  we  have  tried  to  restore,  repair  or 
inactivate  these  abnormal  pathways.  Abatement  of  certain  oncogenic  activity 
led  to  regression  of  tumours,  so  called  tumour  with  oncogenic  addiction. 
However,  relapsed  tumour  with  more  aggressive  phenotype  is  often  observed 
within  various  cancers,  which  may  be  attributed  to  the  pressure  encouraging 
cancer cell evolution and adaptation. A recent popular topic is to understand the 
metabolic signature of tumour cells and find therapeutic targets. Whether the 
metabolic concept is merely another form of oncogenic addiction remains to be 
answered. In addition, it is clear that in addition to genetic alteration, there are 
other components essential for tumour maintenance including microenvironment 
surrounding cancer cells and cancer stem cells. Thus, there is neither a single 
model nor magic bullet in cancer biology. Given PC is an age related disease, it 
is  clear  that  for  PC  the  future  goal  of  research  is  to  delay  the  onset  of  the 
aggressive and metastatic form, which may allow patients to live and manage 
the disease with ease like diabetes. This may reduce PC related mortality and 
morbidity.  
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The graphic abstract illustrates the signalling network of EGFR and HER2, which 
occur at both plasma membrane and endocytic compartments. The trafficking of 
the receptors through EE (early endosome), LE (late endosome) and RE 
(recycling endosome) are critical for the maintenance and amplification of the 
downstream signalling outcome.126 
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